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Tiivistelmä, Finnish summary 
Suomalaisten fosforin saanti on runsasta verrattuna ravitsemussuosituksiin: naisilla saanti 
on keskimäärin 1350 mg/vrk ja miehillä 1800 mg/vrk suosituksen ollessa aikuisväestölle 
600 mg/vrk. Runsas fosforin saanti on haitallista kroonisesta munuaisten vajaatoiminnasta 
kärsiville, mutta viimeaikaisten tutkimusten perusteella se saattaa lisätä myös sydän- ja 
verisuonitautien sekä osteoporoosin riskiä väestötasolla. Fosforia saadaan luontaisesti 
useista eri lähteistä kuten maidosta, lihasta, viljasta, palkoviljasta ja kananmunista. 
Fosforin saanti on kuitenkin lisääntynyt etenkin elintarviketeollisuuden kasvaneen 
lisäainefosfaattien käytön seurauksena. Tieto elintarvikkeiden fosforipitoisuuksista on 
puutteellista; esimerkiksi elintarvikkeiden koostumustietokannat eivät ota huomioon 
lisäaineiden sisältämää fosforia. Elintarvikkeiden lisäaineissa fosfori on epäorgaanisessa 
muodossa, josta sen epäillään imeytyvän käytännössä kokonaan. Sen sijaan useissa 
kasvikunnan tuotteissa fosfori esiintyy osana fytaattia, josta sen imeytyvyys näyttäisi 
olevan selvästi heikompaa kuin eläinkunnan tuotteista. Kuitenkin elintarvikkeen 
prosessointi esim. hapattamalla tai kuumentamalla voi hajottaa osan fytaatista, jolloin 
fosforiakin imeytyy enemmän kuin käsittelemättömästä tuotteesta. Tutkimustietoa fosforin 
imeytyvyydestä ihmisillä on erittäin vähän. Tässä väitöskirjassa tutkittiin elintarvikkeiden 
fosforipitoisuuksia sekä verrattiin eri fosforilähteiden vaikutuksia 
mineraaliaineenvaihduntaan terveillä nuorilla naisilla.  
 
Ensimmäisessä ja toisessa osatyössä määritettiin fosforin saannin kannalta keskeisten, 
omassa tuoteryhmässään yleisimmin käytettyjen tuotteiden kokonais- ja liukoisen fosforin 
pitoisuudet sekä vertailtiin liukoisen fosforin osuutta kokonaisfosforista eri 
elintarvikkeiden välillä. Liukoisen fosforin määrityksessä näytteitä käsitellään 
ruoansulatusta matkien ennen analysointia. Ensimmäisessä osatyössä määritettiin yhteensä 
21 kasviperäisen ruoan ja juoman fosforipitoisuudet. Niiden joukossa suurin 
kokonaisfosforipitoisuus oli kuorimattomilla seesaminsiemenillä (667 mg/100 g), joilla 
liukoisen fosforin pitoisuus oli samanaikaisesti pienin (6%). Kolajuomilla ja oluella 
liukoisen fosforin osuus kokonaisfosforista oli 87-100% (13-22 mg/100 g). Viljatuotteista 
suurin kokonais- (216 mg/100 g) ja liukoisen fosforin osuus (100%) oli teollisilla 
muffineilla, jotka sisältävät natriumfosfaattia kohotusaineena. Palkoviljojen 
keskimääräinen liukoisen fosforin määrä oli 83 mg/100 g (38% kokonaisfosforista). 
Tutkimuksen perusteella fosforin imeytyvyys kasvikunnan tuotteiden välillä voi vaihdella 
paljon. Huolimatta suuresta kokonaisfosforipitoisuudesta, palkoviljatuotteet voivat olla 
melko huonoja fosforilähteitä. Lisäainefosforia sisältävissä tuotteissa liukoisen fosforin 
osuus oli huomattavan suuri, mikä tukee aiempaa käsitystä fosforin tehokkaasta 
imeytyvyydestä epäorgaanisista fosfaattiyhdisteistä.  
 
Toisessa osatyössä määritettiin yhteensä 21 liha- ja meijerituotteen kokonais- ja liukoisen 
fosforin pitoisuus. Suurimmat kokonais- ja liukoisen fosforin pitoisuudet todettiin 
sulatejuustoilla sekä kovilla, kypsytetyillä juustoilla (kokonaisfosforipitoisuus 529-892 
mg/100g), matalimmat puolestaan maidolla ja raejuustolla (108-146 mg/100g). Sekä 
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kokonais- että liukoisen fosforin pitoisuudet olivat matalammat makkaroilla ja leikkeleillä 
kuin sulate- ja kypsytetyillä juustoilla. Broilerin, sian- ja naudanlihan sekä kirjolohen 
kokonaisfosforipitoisuudet (199-232 mg/100g) olivat suunnilleen samalla tasolla, mutta 
liukoisen fosforin pitoisuudessa oli enemmän vaihtelua (147-207 mg/100g). Tässäkin 
tutkimuksessa todettiin lisäainefosforia sisältävillä tuotteilla liukoisen fosforin osuuden 
olevan suuri. Fosfori-proteiinisuhteen sekä natriumpitoisuuden perusteella raejuusto ja 
lisäaineettomat lihat soveltuvat munuaispotilaille paremmin kuin sulatejuustot, kovat 
kypsytetyt juustot, leikkeleet tai makkarat. Eläinkunnan tuotteista fosfori vaikuttaisi myös 
imeytyvän paremmin kuin esimerkiksi palkoviljasta.         
 
Kolmas ja neljäs osatyö olivat ajan ja ravinnon suhteen kontrolloituja 
interventiotutkimuksia nuorilla naisilla. Jokainen tutkittava toimi itse itsensä kontrollina, ja 
tutkimuspäivien järjestys oli satunnaistettu. Kunkin 24 tunnin tutkimusjakson aikana 
kerättiin vuorokausivirtsanäytteet ja otettiin 4 (osatyö III) tai 6 (osatyö IV) verinäytettä, 
joista määritettiin mineraaliaineenvaihdunnan merkkiaineita. Kolmannessa osatyössä 
tutkittiin eri fosforilähteiden akuutteja vaikutuksia mineraaliaineenvaihduntaan 15 
terveellä nuorella naisella. Kontrollijaksolla fosforin (500 mg) ja kalsiumin (250 mg) 
saanti oli niukkaa. Muilla jaksoilla fosforin saanti oli n. 1500 mg, josta 1000 mg saatiin 
vaihdellen lihasta, viljasta, juustosta tai lisäainefosforiseoksesta. Tutkimusruokavaliot 
koostettiin lisäainefosforiseosta lukuun ottamatta tavallisista elintarvikkeista. Seerumin 
lisäkilpirauhashormonipitoisuutta (S-PTH) nosti kontrollipäivään verrattuna ainoastaan 
lisäainefosforiseos. Luun aineenvaihdunnan merkkiaineiden perusteella liha lisäsi sekä 
luun hajoamista että sen muodostumista. Juusto laski seerumin PTH-pitoisuutta ja vähensi 
luun hajoamista. Vilja nosti seerumin fosfaattipitoisuutta vähemmän kuin muut 
fosforilähteet, mikä viittaa siihen, että viljan fosfori on huonommin imeytyvää kuin muista 
fosforilähteistä peräisin oleva fosfori. Fosforilähteiden vaikutukset 
mineraaliaineenvaihduntaan poikkesivat siis toisistaan johtuen fosforin erilaisesta 
imeytyvyydestä ja fosforilähteiden sisältämistä muista ravintoaineista. 
 
Neljännessä osatyössä vertailtiin kahden eri lisäainefosforiyhdisteen, mono- ja 
polyfosfaatin, vaikutuksia fosfori- ja kalsiumaineenvaihdunnan merkkiaineisiin 14 
terveellä nuorella naisella. Jokaisella tutkimusjaksolla koehenkilöt saivat kolme annosta 
joko mono- tai polyfosfaattia tai lumevalmistetta aterioiden yhteydessä. Molemmat 
fosfaattiyhdisteet sisälsivät 1500 mg fosforia/vrk, ja ruokavalio jokaisella jaksolla oli 
täysin sama. Molemmat fosfaattiyhdisteet nostivat seerumin PTH- ja fosfaattipitoisuutta 
sekä lisäsivät fosfaatin eritystä virtsaan. Polyfosfaatti vähensi kalsiumin eritystä virtsaan 
monofosfaattia voimakkaammin, joten se saattaa sitoa kalsiumia suolessa monofosfaattia 
enemmän. Molemmat fosfaattiyhdisteet vaikuttaisivat imeytyvän yhtä tehokkaasti ja 
nostavan PTH-konsentraatiota, mikä pitkään jatkuessaan on haitallista luustolle.  
 
Väitöskirjan tulokset tukevat aiempaa käsitystä siitä, että fosforilähteiden välillä on eroja 
imeytyvyydessä ja vaikutuksessa mineraaliaineenvaihduntaan. Tällä on merkitystä 
kroonisesta munuaisten vajaatoiminnasta kärsivien ruokavaliossa, ja ehkä myös 
laajemmalti, mikäli runsaan fosforin saannin merkitys myös sydän- ja verisuonitautien ja 
osteoporoosin etiologiassa vahvistuu. Lisäainefosfori näyttää imeytyvän tehokkaimmin ja 
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ainakin lyhytkestoisesti vaikuttavan luun aineenvaihduntaan negatiivisesti. Siksi 
lisäainefosforipitoiset tuotteet voivat olla haitallisimpia fosforirajoitteisessa ruokavaliossa 
verrattuna luontaisesti fosforia sisältäviin ruokiin. Fosforilähteen vaikutukset elimistössä 
riippuvat myös sen sisältämistä muista ravintoaineista; terveillä koehenkilöillä kypsytetyn 
juuston vaikutus mineraaliaineenvaihduntaan oli positiivinen johtuen juuston sisältämästä 
kalsiumista. Fosfori-proteiinisuhteen perusteella fosforirajoitteiseen ruokavalioon 
vaikuttaisivat soveltuvan parhaiten lisäainefosfaatittomat palkovilja- ja leivontatuotteet 
sekä eläinkunnan tuotteista raejuusto ja lisäainefosfaatittomat lihat.    
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Abstract 
The phosphorus (P) intake in Finland exceeds the recommended levels, being on average 
1350 mg in women and 1800 mg in men. A high P intake is deleterious to chronic kidney 
disease (CKD) patients, but based on more recent data, it has also been associated with an 
increased risk of osteoporosis and cardiovascular diseases in the general population. In 
addition to several natural sources of P (especially dairy products, meats, whole grains, 
legumes, and eggs), the use of P additives in the food industry is common and further 
increases P intake. P from inorganic additives is believed to be absorbed almost 
completely. However, the food composition databases do not adequately take into account 
the current use of P additives. In several plant foods, P exists as a component of phytic 
acid; less P from plants seems to be absorbed than from animal foods. Processing of a 
food, e.g. by fermenting or heating, may degrade phytate, improving P absorption. Data on 
P content of foods are needed to facilitate research on P intake and its health effects. Data 
on absorbability of P from different food sources and their effects on organs are also 
lacking. In this thesis, P contents of foods were analysed and the effects of different P 
sources on mineral metabolism were compared in healthy young female subjects.    
 
In Studies I and II, the objective was to measure both total phosphorus (TP) and in vitro 
digestible phosphorus (DP) contents of selected foods and to compare the amounts of TP 
and DP and the proportion of DP to TP among different foods. The most popular national 
brands were chosen for analysis. TP and DP contents of 21 products were measured by 
inductively coupled plasma optical emission spectrometry (ICP-OES). In DP analysis, 
samples were digested enzymatically in principle in the same way as in the alimentary 
canal before P analyses. In Study I, TP and DP contents of 21 foods and beverages of plant 
origin were analysed. Among these, the highest amount of TP (667 mg/100 g) was found 
in sesame seeds with hull, which also had the lowest proportion of DP to TP (6%). In cola 
drinks and beer, by contrast, the proportion of DP to TP was 87-100% (13-22 mg/100 g). 
In cereal products, the highest TP content (216 mg/100 g) and DP proportion (100%) were 
present in industrial muffins, which contain sodium phosphate as a leavening agent. 
Legumes contained an average DP content of 83 mg/100 g (38% of TP). These results 
suggest that the absorbability of P may differ substantially among different plant foods. 
Despite high TP content, legumes may be a relatively poor P source. In foods containing 
phosphate additives, the proportion of DP is high, which supports previous conclusions of 
the effective absorbability of P from P additives. 
 
In Study II, TP and DP contents of 21 meat and milk products were measured. The highest 
TP and DP contents were found in processed and hard cheeses; the lowest, in milk and 
cottage cheese. TP and DP contents in sausages and cold cuts were lower than those in 
cheeses. Chicken, pork, beef, and rainbow trout contained similar amounts of TP, but 
slightly more variation was found in their DP contents. In conclusion, foods containing P 
  
 
12
additives have a high DP content. The study confirms that cottage cheese and unenhanced 
meats are better choices than processed or hard cheeses, sausages, and cold cuts for CKD 
patients, based on their lower P-to-protein ratios and sodium contents. The results support 
previous findings of better P absorbability in foods of animal origin than in, for example, 
legumes. 
 
Studies III and IV were controlled intervention studies in healthy young women. Each 
subject served as her own control, and the order of the study sessions was randomized. 
During each 24-h study session 24-h urine collections and four (Study III) or six (Study 
IV) blood samples were taken. Markers of mineral metabolism were measured, and 
analysis of variance with repeated measures was used to compare the study sessions. In 
Study III, acute effects of dietary P from three different food sources and a phosphate 
supplement on calcium and bone metabolism were investigated. Sixteen healthy young 
women participated in Study III. At the control session, calcium intake was ca. 250 mg 
and P intake ca. 500 mg. During the other four sessions P intake was about 1500 mg, 1000 
mg of which was obtained from meat, cheese, whole grains, or a phosphate supplement, 
respectively. The foods served were exactly the same during the P sessions and the control 
session; only P sources varied. Only the phosphate supplement increased serum 
parathyroid hormone (S-PTH) concentration compared with the control session. Relative 
to the control session, meat increased markers of both bone formation and bone resorption. 
Cheese decreased S-PTH and bone resorption. These data suggest that the metabolic 
response was different for different foods. 
 
The purpose of Study IV was to determine whether the effects of mono- and 
polyphosphate salts (MP and PP, respectively) used as additives differ on markers of Ca 
and P metabolism in young women. Fourteen healthy young women participated in the 
study. During each session the subjects received three doses of MP, PP, or a placebo with 
meals in randomized order. Both Pi salts provided 1500 mg P/day, and the diet during each 
session was identical. In both MP and PP sessions, serum phosphate, urinary phosphate, 
and S-PTH increased relative to the control session. PP decreased U-Ca more than did MP. 
The results suggest that PP binds Ca in the intestine better than does MP. Based on the S-
Pi, U-Pi, and S-PTH results, both Pi salts are absorbed with equal efficiency. In the long 
run, increased S-PTH, caused by either an MP or PP salt, could have negative effects on 
bone metabolism. 
 
In summary, the studies support the previous understanding of differences in P 
absorbability and mineral metabolism. This is relevant regarding the diets of CKD 
patients, but may also have a wider relevance if the significance of high P intake in the 
aetiology of cardiovascular diseases and osteoporosis is confirmed. Inorganic P used as 
additives seems to be absorbed more efficiently than P from other sources, and acutely 
affects bone metabolism negatively. Therefore, products containing P additives could be 
more harmful in a P-restricted diet. The effect of a P source also depends on the other 
nutrients that it contains. For example, in healhy subjects, hard cheese affected mineral 
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metabolism favourably due to its high calcium content. Based on P-to-protein ratios, the 
most suitable foods in a P-restricted diet are P-additive-free legumes and bakery products; 
among foods of animal origin, cottage cheese and P-additive-free meats are best.     
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1 Introduction 
Phosphorus (P) is abundantly found in several foods, the main ones being protein-rich 
foods such as dairy products, meat, grain, legumes, nuts, and seeds. In addition, P-
containing additives are commonly used in the food industry in such foods as processed 
cheese and meat products, cola beverages, and bakery products. Differences in P 
absorbability among different food sources appear to exist (e.g. Kalantar-Zadeh et al. 
2010). For instance, P from plant foods seems to be less well absorbed than from other 
sources, as P in plants is often in the form of phytic acid or its salts, which need to be 
hydrolysed for P to be available for absorption in the gut. By contrast, inorganic P used as 
a food additive may be nearly fully absorbed in the intestinal tract (Sullivan et al. 2007, 
Calvo 2000). Current data on food P content and P absorbability are scarce.  
 
The recommended P intake for adults is 600-700 mg/d (Nordic Nutrition 
Recommendations 2013, Institute of Medicine 1997). P intake exceeds these 
recommendations 2- to 3-fold in several countries (Takeda et al. 2002, Gronowska-Senger 
& Kotańska 2004, Paturi et al. 2008, Welch et al. 2009). The use of P additives 
complicates the estimation of total P intake since food composition databases do not take 
into account the use of phosphate additives (Oenning et al. 1998, Sullivan et al. 2007). 
Hence, true P intakes may be higher than those found in studies.  
 
P is needed in the body for maintaining cell structure, energy metabolism in generation of 
adenosine triphosphate (ATP), regulation of cellular signalling through phosphorylation of 
enzymes, maintaining acid-base homeostasis by urinary buffering, and bone mineralization 
as a part of hydroxyapatite. Phosphate homeostasis is regulated by parathyroid hormone 
(PTH), calcitriol, fibroblast growth factor 23 (FGF-23), and several other hormones 
(Berndt & Kumar 2009). During recent years discovery of FGF-23 and other 
phosphatonins, i.e. regulators affecting renal reabsorption of phosphate, has led to better 
understanding of phosphate metabolism and its endocrine linkage to bone, referred to as 
the bone-kidney axis. Even so, less is known about the mechanisms and regulation of 
intestinal phosphate (Pi) absorption than about phosphate handling by the kidney. 
 
A high dietary P intake or high serum phosphate concentration has been associated with 
the aetiology or progression of certain diseases. A P-rich diet may have a negative effect 
on bone metabolism (Reiss et al. 1970, Brixen et al. 1992, Kärkkäinen & Lamberg-Allardt 
1996, Kemi et al. 2006), which, in the long run, could lead to lower bone mineral density 
and osteoporosis. In chronic kidney disease, the ability to excrete phosphate is gradually 
lost. Therefore, to avoid complications related to hyperphosphatemia, treatment of Pi 
retention requires dietary P restriction with or without P binding medication. Early 
treatment of Pi retention or hyperphosphatemia may prevent or slow the development of 
the kidney disease. Recently, higher serum Pi levels even within the normal range have 
also been associated with increased risk of cardiovascular disease in healthy populations 
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with intact kidney function (Larsson et al. 2010, Foley et al. 2009, Foley et al. 2007, 
Dhingra et al. 2008). 
 
Data on P content of foods are needed not only to be able to evaluate P intake of renal 
patients, but also to study P intake and its effects on health at the population level. Data on 
bioavailability of P from different food sources are also lacking. In this work, P content of 
foods, absorbability of P, and the effect of P on mineral metabolism are discussed.        
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2 Review of the literature 
2.1 Phosphorus in foods 
Even though most foods contain phosphorus (P), its main sources are protein-rich foods 
such as dairy products, meat, fish, eggs, legumes, nuts, and whole-grains (e.g. Calvo & 
Uribarri 2013). Total P per gram of protein is similar in plant and animal foods, ca. 20 
mg/g protein in cheese, beef, lentils, and peas (Massey 2003). Regression equations to 
depict the association between protein and P intake have been developed (Boaz & Smetana 
1996, Kalantar-Zadeh et al. 2010). In the study of Boaz and Smetana (1996), the following 
regression equation accounted for 84% of the variance in dietary P intake: 
Dietary P (mg) = 128 mg P + (dietary protein in g) x 14 mg P / g protein.  
In the study of Colman et al. (2005), the following regression equation accounted for 83% 
of the variation: 
Dietary P (mg) = 78 mg P + (dietary protein) x 11.8 mg P / g protein.  
It has been pointed out that these equations are not necessarily suitable for predicting 
individual P intakes (Agarwal & Agarwal 1997), but they illustrate the relationship 
between these two nutrients.  The common use of P-containing additives further 
complicates this association (Kalantar-Zadeh et al. 2010). 
2.1.1 Analysis of food phosphorus content 
Foods are complex chemical systems in which multiple chemical reactions and 
interactions, as well as physical phenomena, are likely to occur (Molins 1991). This 
complicates nutrient analyses of foods. In P analysis, for example, meats contain 
phosphate hydrolytic enzymes capable of catalysing polyphosphate breakdown even at 
subzero temperatures, altering the composition of the added phosphates at rates that vary 
with product storage conditions. Furthermore, foods are able to bind, depolymerize, or 
otherwise affect phosphates to the extent of making them undetectable by the traditional 
analytical techniques used in pure phosphate solutions. Currently, several methods are 
used to analyse P content of foods.    
 
In colorimetric methods, phosphates are converted to a coloured compound through a 
chemical reaction, which can then be detected, as the intensity of a colour is related to the 
amount of P in the sample. For example, in the validated method of the Nordic Committee 
on Food Analysis for P determination in food, the sample is dry-ashed to remove organic 
material (Nordic Committee on Food Analysis 1994). The acid-soluble inorganic residue 
is used for a colour reaction based on the formation of a blue complex between Pi and 
sodium molybdate in presence of ascorbic acid as a reducing agent. The intensity of the 
blue colour is measured spectrophotometrically. Cupisti et al. 2006, Benini et al. 2011, 
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and Cupisti et al. (2012) have used the molybdenum blue method in their P analyses. Moe 
et al. (2011) measured “photometrically” the P contents of the diets in their crossover trial, 
but did not describe their method more specifically.  
 
The molybdenum blue method has many applications (Molins 1991). For instance, several 
reducing agents have been used successfully to develop the molybdenum blue colour for 
analysing P in diverse foods. Another colorimetric method uses vanadomolybdate reagent, 
which produces a yellow compound when reacting with phosphates (Olsen & Sommers 
1982). The official method of AOAC International 965.17 for P analysis (Phosphorus in 
Animal Feed and Pet Food) is similar to this method. The P contents of several grain 
products in the Finnish food composition database Fineli® (National Institute for Health 
and Welfare 2011) are based on the findings of Varo et al. (1980), who used a 
vanadomolybdate method in their analyses (Saari & Paaso 1980).   
 
AOAC Official Method 964.06 (Phosphorus in Animal Feed) is also used in food analyses. 
In this titrimetric method, molybdate solution and sodium hydroxide are used as reagents. 
Phenolphtalein is added to produce a pink colour, which is titrated with standard acid. 
Another official method for determining P in flour (AOAC Official Method 948.09 
Phosphorus in Flour) has been published. In this method, either magnesium nitrate 
solution or molybdate solution can be used as reagents. Similarly to the former method, 
the pink colour is titrated with standard acid. 
 
P content of a food can also be measured by inductively coupled plasma atomic emission 
spectroscopy (ICP-AES), also referred to as inductively coupled plasma optical emission 
spectrometry (ICP-OES). ICP-OES is a type of emission spectroscopy using the 
inductively coupled plasma to transform atoms of the sample into the excited state and 
also to ionize them. The excited atoms and ions emit electromagnetic radiation at the 
wavelengths characteristic of a particular element, and the intensity of this emission is 
indicative of the concentration of the element in the sample. AOAC Official Method 
984.27 (Calcium, Copper, Iron, Magnesium, Manganese, Phosphorus, Potassium, Sodium, 
and Zinc in Infant Formula) is based on ICP-OES. Sullivan et al. (2007), Sherman & 
Mehta (2009a), Sherman & Mehta (2009b), and León et al. (2013) have used ICP-OES in 
their analyses of meat P content. An X-ray fluorescence method for analysing P in meat 
products has also been published (Jastrzębska et al. 2010). 
 
Recently, methods to detect different fractions of P in foods have been developed (Benini 
et al. 2011, Cupisti et al. 2012, Itkonen et al. 2012). Itkonen et al. (2012) tested a method 
for analysing digestible P content of foods, which is expected to represent the amount of 
bioavailable P. This method is based on enzymatic assay of insoluble and soluble dietary 
fibre (Asp et al. 1983). The proteins and starch of the sample are degraded with alimentary 
enzymes and the mineral content in the remaining fibre is analysed. Ekholm et al. (2000, 
2003) developed the method for the analysis of soluble minerals. Digestible P was 
analysed using an inductively coupled plasma-mass spectrometry (ICP-MS) (Itkonen et al. 
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2012). The authors concluded that the new method for digestible P analysis is reliable, but 
requires validation by in vivo tests. 
 
Benini et al. (2011) determined total and soluble P contents of three types of meat 
products prepared both with and without P additives. Soluble Pi ions were extracted with a 
slight modification in a procedure described previously by Jastrzębska et al. (2008).  Both 
total and soluble P were analyzed by a spectrophotometrical molybdenum blue method 
(Benini et al. 2011). Subsequently, the same authors described a novel method for 
analysing three different P subtypes of ham (inorganic P including added preservatives and 
natural P derived from phospholipids and phosphoproteins) separately (Cupisti et al. 
2012). In this method, inorganic P was measured similarly to the soluble P analysis 
previously reported (Benini et al. 2011). For the analysis of P in phospholipids, lipid 
extraction was performed, and P content of the lipid extract was measured (Cupisti et al. 
2012). P content of phosphoproteins was measured after precipitation of trichloroacetic 
acid. The authors conclude that their novel method is feasible and can accurately detect the 
added P additives in meat products. They also believe the method can be extended to all 
common foods of both animal and plant origin, also including determination of P from 
phytate in plant products (Cupisti et al. 2012).  
2.1.2 Phosphorus sources 
2.1.2.1 Natural sources   
In cow milk, the concentration of P is ca. 95 mg/100 g (Gaucheron 2011). The P content of 
human milk is much lower, 10 mg/100 g according to the Finnish food composition 
database Fineli® (National Institute for Health and Welfare 2011). The highest P contents 
in dairy foods are found in hard and processed cheeses (500-800 mg/100 g), the lowest in 
milk and fresh cheeses (e.g. Gaucheron 2011). The P contents of selected dairy products 
are shown in Appendix I, Table 1. The chemical composition of P in milk is complex. 
Milk contains both organic and inorganic phosphates. Organic phosphate is phosphate 
bound to organic molecules of milk such as casein, phospholipids, RNA, DNA, 
nucleosides, nucleotides, and sugar phosphate. Phosphates associated with casein 
molecules are in the micellar phase, and phosphates with other organic molecules of milk 
are in the aqueous phase. Inorganic phosphates are distributed between the aqueous and 
micellar phases. In casein micelles, both organic and inorganic phosphates are associated 
with calcium (Ca). These associations between Ca and phosphate form granules known as 
nanoclusters. During preparation of dairy products inorganic phosphates can be transferred 
to the aqueous phase (Gaucheron 2011). Hence, part of P is lost in whey during cheese 
making. This partly explains the different amounts of P in different dairy products. 
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Phosphorus in muscle protein foods occurs as phosphate bound to amino acid side chains, 
but also as phospholipids and nucleotides (Massey 2003). The P contents of raw (lean and 
boneless) meats are similar, with the exception of reindeer, the P content of which is 
higher than in other meats based on Fineli® (Appendix I, Table 2). In liver and kidney, the 
P content is higher than in muscle meats; on average 390 and 260 mg, respectively 
(National Institute for Health and Welfare 2011). In eggs, almost all P is in the egg yolk 
(Kalantar-Zadeh et al. 2010).  
 
The P content of fishes varies among species. The P contents of salmon and rainbow trout, 
which are commonly consumed in Finland, are 240 and 260 mg/100 g, respectively 
(National Institute for Health and Welfare 2011). Among raw filleted marine fish species, 
the lowest P content has been found in broomtail grouper (103 mg/100 g) and the highest 
in pompano (287 mg/100 g) (Castro-González & Miranda-Becerra 2010). Fatty fishes 
seem to have higher P content than lean fishes. Furthermore, because fish bones consist of 
calcium phosphate, their P content is high. Therefore, small fishes consumed with their 
bones, such as canned sardines (Gastro-González et al. 2010), have relatively high P 
content (279-304 mg/100 g). Variation also in the P content of molluscs has been found 
(Castro-González & Miranda-Becerra 2010).   
 
When considering both meats and fishes, cooking is likely to alter their P content, 
probably depending on the specific cooking method (Sherman & Mehta 2009a). Boiling 
foods may reduce P retention as compared with raw samples (Cupisti et al. 2006). Also 
soaking in water (before cooking) reduces the P content of a food (Jones 2001). Although 
data on the effect of other cooking methods on the P content of foods do not exist, the P 
content of cooked meat or fish may often be higher than that of raw food (National 
Institute for Health and Welfare 2011), as the water content of cooked meat is lower than 
that of raw meat.   
 
Among plant foods, most fruits and vegetables contain only small amounts of P (Kalantar-
Zadeh et al. 2010). By contrast, organic P is found abundantly in seeds, nuts, and legumes, 
but also in cereals. Chocolate, which is made from the seed of the cacao tree flower, is also 
a P-rich food, the highest amounts being found in milk chocolate (Noori et al. 2010). P in 
plants is often in the form of phytic acid (myoinositol hexaphosphate), its free salt phytate, 
or its Ca/magnesium (Mg) salt phytin (Plaami 1997). In seeds, 60-90% of the total P 
occurs as phytic P (Ravindran et al. 1994, see Plaami 1997). The proportion of phytate P is 
much lower (10-25%) in tubers (Ravindran et al. 1994). In legumes, phytate content 
differs among species and forms, with broad beans having the highest and lentils the 
lowest content (Elhardallou & Walker 1994). In cereals, phytate is mostly located in the 
aleurone layer and the germ, while the endosperm is almost free of phytate (O’Dell et al. 
1972). Hence, whole-grain products have a higher P content than hulled products. Varying 
degrees of phytates are also present in fruits and vegetables. Leafy vegetables seem to be 
an exception, as they are practically devoid of phytate.  
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The bioavailability of P from phytic acid and its salts is lower than in P from foods of 
animal origin (see Section 2.1.3). Furthermore, food composition databases may not be 
accurate in their plant-food P contents, as Moe et al. (2011) found a 33% lower P content 
in a laboratory-analysed grain- and soy-based diet than that predicted from the database, 
while the P content of a meat-based diet was predicted correctly by the database. P 
contents of selected plant foods are shown in Appendix I, Table 3.    
2.1.2.2 Phosphorus-containing food additives 
Several P-containing food additives are used by the food industry (Kalantar-Zadeh et al. 
2010, Uribarri 2007). In the European Union, all additives in packed foods are required to 
be designated by their category, indicating the purpose of the additive followed by either 
the specific name of the additive or an E code for permitted additives (European Council 
2000). In other countries, e.g. in the United States, identification of products with P-
containing additives may be less consistent (e.g. Sullivan et al. 2007). The P-containing 
additives with their E codes are shown in Appendix II.   
 
P-containing additives are used for a number of reasons, enabling food products to 
achieve, for example, better texture, taste, emulsification, acidification, leavening, anti-
caking, moisture binding, antimicrobial action, colour stability, iron binding, buffering, 
and freeze-thaw stability (Calvo & Uribarri 2013). The use of P-containing additives is 
very common in the meat industry, where they are used in both raw and cooked meats, 
sausages, and other restructured meats. In dairy products, P additives are most commonly 
found in processed cheeses, in which phosphates function as melting salts. Cola and some 
other soft drinks contain varying amounts of phosphoric acid to affect the colour, texture, 
or taste of these beverages (Gutekunst 2010, Ritz et al. 2012). Another reason speculated 
for using phosphoric acid in soft drinks instead of citric or tartaric acid is its cheaper price 
and ability to produce greater sourness (Uribarri 2007). 
 
Bakery products containing sodium phosphate as a baking powder are also a common P 
additive-containing group of foods (Uribarri 2007). In addition, as phosphates prevent 
agglomeration of food powders, they are used in different types of instant products such as 
powdered coffee and pudding (Ritz et al. 2012). Frozen fish products are commonly rinsed 
before freezing in a solution of 12.5% sodium tripolyphosphate to prevent loss of proteins 
during thawing (Uribarri 2007). Frozen foods (72%) were the most common P additive-
containing food group in a study reviewing nearly 2400 best-selling branded grocery 
products in northeast Ohio for P additives (León et al. 2013). Other food groups 
commonly containing P additives were dry food mixes (70%), packaged meat (65%), 
bread and bakery products (57%), soup (54%), and yogurt (51%).  
 
Based on analyses on several meat products, P additives substantially increase the P 
content of the product relative to a similar product prepared without P-containing additives 
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(Sullivan et al. 2007, Sherman & Mehta 2009a, Sherman & Mehta 2009b, Benini et al. 
2011, Cupisti et al. 2012). The difference in P content to a product prepared without 
additives may be up to twofold (Sherman & Mehta 2009a). Furthermore, food composition 
databases may underestimate P contents of foods (Sullivan et al. 2007). The variation in 
the use of P additives in similar kinds of products complicates the estimation of P content 
of a product or a diet. Table 1 shows the P content of cooked ham prepared with or without 
P additives based on different sources. The method described by Cupisti et al. (2012) to 
quantify different subtypes of P in meat products could help to estimate P intake 
originating from additives. So far, analysed data on the effect of P additives on the P 
content of a single product are not available in food groups other than meats. However, 
León et al. (2013) measured P contents over four days in sample meals created from local 
best-selling branded grocery products with and without P additives. Sample meals 
comprising mostly P additive-containing foods had >700 mg more P/day than meals 
consisting of only additive-free foods. P additive-free meals were, however, more 
expensive than P additive-containing meals.   
 
Table 1. Phosphorus content of cooked ham prepared with and without additives based on 
different sources. 
Phosphorus content in cooked ham (mg /100 g)   Source 
Without additives With additives  
194±7 296±47 Benini et al. 2010 
185±17 270±46 Cupisti et al. 2012 
*200 (fat content 4.5%) Fineli® 
*160 (fat content 3.1%) Fineli® 
*239 (water added, boiled) U.S. Dept of Agriculture (2012) 
*Use of P additives not mentioned 
2.1.3 Bioavailability of phosphorus 
With regard to nutrients, bioavailability usually designates the quantity or fraction of the 
ingested dose absorbed (Heaney 2001). However, bioavailability may also include 
transport of nutrients to organs and cells, where they finally fulfill their physiological 
function (Schlemmer 1995). Schlemmer (1995) notes that bioavailability is not merely a 
question of a nutrient’s features that allow the nutrient to be utilized, but is also affected by 
factors of different individuals such as requirement of the nutrient, age, sex, etc. For 
simplicity, bioavailability here is considered similarly to Heaney’s above-mentioned 
definition. 
 
Several in vivo methods are used to estimate bioavailability (Heaney 2001). The classic 
balance method means measuring the difference between the ingested amount of a nutrient 
  
 
26
and the amount found in faeces. This method is, however, imprecise, time-consuming, 
laborious, and expensive. If combined with intestinal lavage, it is more accurate and 
simpler to perform. Measurement of the serum concentration of a nutrient after ingestion 
does not yield absolute bioavailability values, but can be used in comparisons of two or 
more preparations. The problem regarding this method is the homeostatic regulation of 
serum concentrations, which may actively damp the absorptive rise. According to Heaney 
(2001), using either radioactive or stable tracers in evaluating bioavailability would appear 
to be optimal for most nutrients. The tracer method is sensitive, but its limitation is that it 
requires that the source can be intrinsically labelled. In vitro digestion models are methods 
in which enzymatic degradation of food is simulated outside the body (Hur et al. 2011). 
Compared with in vivo methods, they are more rapid and economic, but less accurate.    
 
Of natural P sources in a mixed diet, 60-80% is absorbed in the intestine, as measured by a 
balance method combined with intestinal lavage (Ramirez et al. 1986). The absorption rate 
of P from an individual food may, however, differ substantially depending on the form of 
P found in the food and other nutrients of the meal (e.g. Uribarri 2007, Kalantar-Zadeh et 
al. 2010). The physiology of P absorption is discussed in Section 2.3.2. 
 
In milk, P absorbability differs among different fractions (Uribarri & Calvo 2003). The P 
in casein micelles is of lower bioavailability. On the other hand, dairy foods contain 
abundant Ca, which complexes with phosphate in the intestine, thereby reducing its 
absorption (Heaney & Nordin 2002). Ca supplements are commonly utilized in the 
treatment of hyperphosphatemia in chronic kidney disease to bind dietary P (Nolan & 
Cunibi 2003). Hence, theoretically, P from dairy foods could have a relatively low 
bioavailability. However, based on increased serum phosphate levels after both cheese and 
milk ingestion in a controlled human study, P from dairy foods seems to be absorbed 
efficiently (Kärkkäinen et al. 1997). In a rat study, P from casein affected phosphate 
metabolism more profoundly than the same amount of P from grains, implying relatively 
good P bioavailability from the former (Moe et al. 2009). In addition, the Institute of 
Medicine (1997) states that there is “no significant interference with phosphorus 
absorption by calcium at intakes within the typical adult range”. P absorption is more 
efficient from human milk than from cow milk (Williams et al. 1970).   
 
Also, data on P bioavailability from meat are scarce, even though generally P from meat is 
considered to be well absorbed (Uribarri 2007). Based on a balance study in healthy young 
men, P from meat is absorbed efficiently (Schuette & Linkswiler 1982). From 
hydroxyapatite, P seems to be well absorbed, based on an experimental study in healthy 
volunteers fed bone meal powder (Tsuboi et al. 2000). However, P in bone meal powder 
(hydroxyapatite) is in a different form than in meat. The results of Tsuboi et al. (2000) 
could be extrapolated to P absorbability from bony fish as bones from other animals are 
not normally consumed.  
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In plant foods, phytates need to be hydrolysed for P to be available for absorption. Phytate 
hydrolysation may occur enzymatically by phytase enzyme or non-enzymatically via acid, 
high temperature, or pressure (Plaami 1997). Phytase enzymes are found in plants, 
microbes, and some animal tissues. In humans, phytase activity is very low in the gut 
(Iqbal et al. 1994), but processing of foods by soaking, germinating, or fermenting reduces 
phytate content by activating intrinsic phytase (Beal & Mehta 1985). Boiling and steaming 
also degrade phytates (Plaami 1997). During bread-making phytic acid content of the 
bread is decreased due to both the activation of phytases present in the flour and high 
temperature. Baker’s yeast has phytase activity, and a larger amount of phytic acid is 
degraded in breads leavened with yeast than in breads prepared without it (Türk & 
Sandberg 1992). However, also souring degrades phytic acid based on a recent in vitro 
study, in which non-soured cereals contained lower percentages of digestible P than soured 
cereals (Itkonen et al. 2012). Furthermore, several other factors contribute to phytate 
degradation in doughs such as particle size of flour, pH, temperature, water content, and 
fermentation time (Plaami 1997). Also, phytase activity and its heat resistance may differ 
among different grains (McCance & Widdowson 1944). In any case, a larger amount of P 
is likely to be bioavailable from cooked or otherwise processed plant foods than from raw 
or unprocessed foods.  
 
The bioavailability of P from phytic acid-containing plant foods has mostly been studied in 
farm animals. The only human study on the effect of phytic acid on P absorption is in 
ileostomic patients, in whom phytic acid reduced absorption of P (Kivistö et al. 1986). 
Similar results were found more recently, as a vegetarian diet caused lower serum Pi 
concentration than a meat-based diet in a crossover trial in chronic kidney disease patients, 
implying thus lower bioavailability for vegetarian than for meat P sources (Moe et al. 
2011). Adding phytase to the feed of pigs and chickens has been shown to improve P 
bioavailability (Simons & Versteegh 1990, Sands et al. 2001, Liu et al. 2007). Compared 
with conventional feed, P absorbability from low-phytate soybean (Dilger & Areola 2006) 
and barley (Veum et al. 2002) has been improved in chicken and in pigs, respectively.  
 
P additives in foods are inorganic compounds, which are not protein-bound (Kalantar-
Zadeh et al. 2010). For this reason, it has been estimated that inorganic P compounds more 
readily dissociate in the gut, and more than 90% of inorganic P may be absorbed in the 
intestinal tract (Calvo 2000, Sullivan et al. 2007). Hence, P additives not only increase the 
P content of the food, but also the proportion of absorbable P compared with foods 
containing only natural P. The bioavailability of P additives may differ, as polyphosphates 
have caused a more severe nephrocalcinosis in rats than monophosphates (Matsuzaki et al. 
1999, Matsuzaki et al. 2001). However, monophosphates may increase PTH secretion 
more than polyphosphates (Zemel & Linkswiler 1981).      
 
Contrary to phytic acid-containing foods, processing might also impair the bioavailability 
of P, as consumption of a Maillard reaction product (MRP) -rich diet had a negative 
influence on dietary P absorption, compared with a diet low in MRPs (Delgado-Andrade et 
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al. 2011). Processing of foods with high protein and carbohydrate and/or fat content 
favours development of the Maillard reaction and formation of browning products, 
especially by frying, roasting, grilling, baking, and reheating. Thus, MRPs are formed 
especially during the manufacturing of snacks and fast foods. For this reason, increased 
snacking and fast food consumption are thought to impair bioavailability of P and other 
minerals (Delgado-Andrade et al. 2011). 
 
Of other nutritional interactions affecting P bioavailability, pharmacological doses of 
nicotinamide (Eto et al. 2005), and aluminium (Rutherford et al. 1973) prevent P 
absorption in the intestine. Polyphenols of tea seem not to affect P absorption based on a 
rat study on white tea extract (Pérez-Llamas et al. 2011). Taken together, P bioavailability 
depends on the predominant food groups, the degree of processing of the foods, and the 
amount of P additives in the foods consumed. Still, P is absorbed more efficiently than 
several other minerals.  
2.2 Dietary requirements, guidelines, and intake of phosphorus 
The recommended intake of P in adults set by the Nordic Nutrition Recommendations is 
600 mg/d (Nordic Nutrition Recommendations 2013). The recommended daily allowance 
(RDA) for adults aged ≥19 years by the Institute of Medicine (1997) is 700 mg/d. The 
RDA for children aged 9-18 years is substantially higher, 1250 mg/d, due to an estimated 
additional need during growth. In Table 2, the recommended intakes of P for different age 
groups according to the Nordic Nutrition Recommendations and the Institute of Medicine 
are compared.  
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Table 2. Recommended intake of phosphorus by the Nordic Nutrition Recommendations 
(2013) and the dietary reference intakes of the Institute of Medicine (1997). 
Nordic Nutrition Recommendations 
2013 
Recommended daily allowance 
Age/life stage Recommended P 
intake (mg/d) 
Age/life stage Recommended P 
intake (mg/d) 
<6 mo - 0-6 mo 100* 
6-11 mo 420 7-12 mo 275* 
1-5 y 470 1-3 y 460 
6-9 y 540 4-8 y 500 
10-17 y 700 9-18 y 1250 
≥18 y 600 ≥19 y 700 
Pregnancy 700 Pregnancy 700 
Lactation 900 Lactation 700 
*Adequate intake 
 
The dietary recommendations for P by the Institute of Medicine (1997) have been set 
using balance studies and serum inorganic P (S-Pi) concentrations. The level required to 
maintain S-Pi within an optimal range has been considered an indicator of P nutrition. For 
infants and children, the recommendations are based on estimates of the need for P during 
growth.  
 
Some variation exists in the highest acceptable intake of P among different 
recommendations. The tolerable upper intake level (UL) of P set for children aged 1-8 
years and adults >70 years is 3 g/d, whereas UL for individuals aged 9-70 years is higher, 
4 g/d (Institute of Medicine 1997). For pregnant women, the UL is 3.5 g/d. The European 
Food Safety Authority (EFSA) has not established an upper intake level for P, but states 
that healthy individuals can tolerate P intakes of “up to at least 3000 mg/d without adverse 
systemic effects” (EFSA 2005). According to the Nordic Nutrition Recommendations 
(2013), the tolerable upper intake level has to be re-evaluated during the coming years due 
to recent observations on adverse effects of P. 
 
Compared with the recommended intakes, the average P intake of adults is generous based 
on data from several countries (Takeda et al. 2002, Gronowska-Senger & Kotańska 2004, 
Paturi et al. 2008, Welch et al. 2009). In Finland, the mean intake of P among 25- to 64-
year-olds was 1326 mg/d in women and 1778 mg/d in men (Paturi et al. 2008). In the 
EPIC study, geographical variation in P intakes among 35- to 74-year-old adults in 10 
European countries was reported (Welch et al. 2009). In men, the lowest intake (1425 
mg/d) was found in the United Kingdom in a cohort consisting predominantly of 
vegetarians, and the highest (2070 mg/d) in Greece. In women, P intakes ranged from 
1089 mg/d in Ragusa, Italy to 1478 mg/d in Aarhus, Denmark. In the USA, P intakes in 
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the 2005-2006 National Health and Nutrition Survey (NHANES) were 1727 mg and 1197 
mg in men and women, respectively (Calvo & Uribarri 2013). In the 2009-2010 survey, 
the intakes were slightly higher, which may be due to updates in the P content of food 
composition data (Calvo & Uribarri 2013). 
 
P intake may be adequate despite lack of several other nutrients in the diet, as observed in 
Turkish adolescents (Garipagaoglu et al. 2008). On the other hand, relatively low P intakes 
(649 mg/day) have been found in Japanese 20- to 23-year-old female college students 
together with inadequate Ca, protein, and potassium (K) intakes (Ueno et al. 2005). 
Heaney (2004) has raised the question of whether P intakes of older women taking Ca 
supplements are adequate, considering the low P intakes (10-15%) of women in this age 
group, and the P-binding capacity of Ca supplements. Furthermore, individuals with a 
lower socio-economic status and a lower income have a higher serum Pi, possibly 
indicating higher P intake due to fast food and preprepared meal consumption (Gutiérrez et 
al. 2010).      
 
The use of P additives complicates estimation of total P intake since current food 
composition databases do not take into account the use of phosphate additives (Oenning et 
al. 1998, Sullivan et al. 2007). The true average intakes in Western countries may 
therefore be substantially higher than the current data show. Recently, in the USA, nutrient 
contents have been revised for chicken breasts and pork to reflect the use of P additives 
(Calvo & Uribarri 2013), but when regarding all P additive-containing foods, the need for 
more extensive updates exists. It has been estimated that in 1990 P intake from additives 
was about 500 mg/day in the USA (Calvo & Park 1996). However, already in the 1970s, 
Bell et al. (1977) calculated that depending on the food choices, P intake from additives 
could rise to 1 g/day. In Europe, Benini et al. (2010) have estimated that P additives 
increase the daily P intake by at least 100-300 mg/day in hemodialysis patients. In a recent 
study comparing the P content of top-selling foods with and without P additives, meals 
comprising mostly phosphorus additive-containing foods had 736 mg more P per day 
compared with meals consisting of only additive-free foods (León et al. 2013). 
2.3 Metabolism of phosphorus 
2.3.1 Function and distribution 
P is needed in multiple biological processes. P-containing compounds are needed in the 
cell structure for maintenance of membrane integrity and nucleic acids, energy metabolism 
in generation of ATP, regulation of cellular signalling through phosphorylation of 
enzymes, maintenance of acid-base homeostasis by urinary buffering, and bone 
mineralization as a part of hydroxyapatite. In biological systems, P is present as phosphate, 
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i.e. H2PO4- and HPO42-. It is the most abundant anion in the human body, comprising ca. 
1% of total body weight (Penido & Alon 2012). 
 
Most (85%) of the P in body content is in the bone and teeth, 14% in soft tissues, and only 
1% in the extracellular space (Penido & Alon 2012). In the extracellular fluid, one-third of 
the P content is complexed to Na, Ca, and Mg, one-tenth is bound to proteins, and the rest 
is present as inorganic Pi. The serum Pi (S-Pi) concentration is determined by the balance 
between intestinal absorption of Pi from the diet (16 mg/kg/day), storage of Pi in the 
skeleton (3 mg/kg/day), and excretion of Pi through the urine (13 mg/kg/day) (Berndt & 
Kumar 2009). Central endocrine factors affecting these processes are parathyroid hormone 
(PTH), calcitriol (1,25(OH)2D3), and phosphatonins such as fibroblast growth factor-23 
(FGF-23). In the following sections, P homeostasis and its regulation are reviewed in more 
detail. 
 
Measuring the S-Pi content is the gold standard to estimate the overall Pi status of the 
body (Osuka & Razzaque 2012). However, as S-Pi is regulated homeostatically, its 
abnormal concentrations are often a sign of a metabolic disturbance caused by, for 
instance, an illness. The normal range for S-Pi concentration is 0.8-1.5 mmol/l in adults. 
Infants have the highest physiological (1.5-2.65 mmol/l) S-Pi concentration due to rapid 
bone growth and soft tissue buid-up. In addition to variation with age, S-Pi concentration 
varies over the course of the day, with a decrease to a nadir just before noon, an increase to 
a plateau in late afternoon, and a small further increase to a peak shortly after midnight 
(Portale et al. 1987). This diurnal variation may be substantially blunted in advanced 
chronic kidney disease patients (Moe et al. 2011). Also P intake from meals during the day 
strongly affects S-Pi concentrations   
2.3.2 Intestinal absorption 
Dietary P is absorbed as inorganic Pi throughout the small intestine. The duodenum seems 
to play an important role in the acute response to a high-P diet, whereas the jejunum is 
more significant in the chronic adaptation to a low-P diet (Giral et al. 2009). Two distinct 
mechanisms exist in Pi absorption: a passive paracellular pathway and active transport 
through the sodium-dependent phosphate co-transporters situated at the intestinal brush 
border membrane (Sabbagh et al. 2011). The paracellular transport of Pi by diffusion is 
largely dependent on the concentration of P present in the intestine. The paracellular 
pathway has been considered the major route of Pi entry (Kayne et al. 1993). However, 
based on recent studies on rats, at least in postprandial conditions, active transport has 
been shown to contribute up to 50% of the total P uptake (Sabbagh et al. 2009). Still, the 
importance of the paracellular route is supported by the early finding that Pi absorption 
remains relatively effective even at extremely low plasma 1,25(OH)2D3 concentrations 
(Wiltz et al. 1979).  
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Several sodium-dependent Pi transporters exist (Murer et al. 2004). Type IIb sodium-
dependent Pi transporter (Npt2b) is the major handler of P in the intestine; >90% of active 
intestinal P transport occurs through Npt2b (Sabbagh et al. 2011). Npt2b has a preference 
for divalent Pi (HPO42-), and it transports Pi with a stoichiometry of 3 Na ions: 1 
phosphate (Marks et al. 2010). Energy for the Pi transport across the brush border 
membrane is provided by the Na gradient (outside>inside) maintained by Na+K+ATPase at 
the basolateral membrane (Carpenter 2010). Inside the enterocyte, restricted channels, 
such as microtubules, carry Pi from the apical pole to the basolateral pole of the cell. Very 
little is known about the processes involved in the exit of Pi across the basolateral 
membrane into the circulation (Marks et al. 2010). The intestinal absorption of Pi is 
depicted in Figure 1.    
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HPO42-
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Na+ Na+
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Figure 1 P absorption in the enterocyte (modified from Carpenter 2010). Active transport 
occurs through Npt2b, and passive diffusion takes place paracellularly. 
Na+K+ATPase maintains the sodium gradient required for active transport. Exit of Pi 
from the enterocyte across the basolateral membrane is poorly understood. 
The amount of Npt2b is increased by 1,25(OH)2D3 and dietary Pi restriction (Hattenhauer 
et al. 1999). PTH stimulates Npt2b indirectly, through its stimulatory effect on 
1,25(OH)2D3 synthesis (Penido & Alon 2012). Among the phosphatonins, which are a 
group of phosphaturic proteins regulating Pi homeostasis, matrix extracellular 
phosphoglycoprotein (MEPE) seems to be the only one affecting intestinal Pi absorption 
directly (Marks et al. 2008). In mice, MEPE inhibits Pi transport in the jejunum, but not in 
the duodenum. Other factors affecting intestinal Pi absorption include glucocorticoids, 
oestrogens, and metabolic acidosis (Penido & Alon 2012). Furthermore, there is an age-
related decline in Pi absorption that is correlated with decreased gene and protein 
expression of Npt2b (Xu et al. 2002). 
  
 
33
 
Relatively recently, it has been discovered that the amount of intestinal Pi can rapidly 
modulate renal Pi reabsorption (Berndt et al. 2007). In fact, when intestinal Npt2b is 
downregulated, there is an increase in renal sodium-dependent Pi transporter 2a (Npt2a), 
increasing Pi reabsorption (Sabbagh et al. 2009). It has been proposed that small intestinal 
mucosa secretes a thus far unknown substance, “intestinal phosphatonin”, which regulates 
this renal-gastrointestinal axis. MEPE has been postulated to be this substance (e.g. Marks 
et al. 2010). The findings on the signalling axis between the intestine and the kidney 
suggest that intestinal Pi absorption plays a more significant role in Pi homeostasis than 
previously recognized. Still, less is known about the mechanisms and regulation of 
intestinal Pi absorption than about phosphate handling by the kidney. For example, it is not 
known whether Npt2b dominates only under fasting or low Pi conditions and whether Na-
independent transport has a more important role in overall Pi absorption. Furthermore, 
regional-specific adaptations of intestinal Pi transport to acute and chronic Pi loads may 
exist. Even so, it seems that the main determinants of how much P is absorbed in the 
intestine are the P intake, its bioavailability, and the presence of either natural or 
pharmacologic P binders (Uribarri 2007). 
2.3.3 Excretion 
Renal excretion is the most important regulator of Pi homeostasis. Most (80%) of the Pi in 
the primary urine is reabsorbed in the proximal tubules. In the tubular cells, there is no 
paracellular transport of Pi, but Pi is absorbed by Npts (Biber et al. 2009). Npt2a has been 
localized throughout the proximal tubule (Custer et al. 1994) and is responsible for ~70% 
of Pi reabsorption in mice (Beck et al. 1998). Like Npt2b, Npt2a preferentially carries 
divalent Pi (HPO42-) and transports it with a stoichiometry of 3 Na ions: 1 phosphate 
(Marks et al. 2010). PTH, FGF-23, and dietary Pi are considered to be the most important 
regulators of Npt2a protein levels. Expression of Npt2a is reduced within minutes to PTH, 
and within 2 h in response to a change in dietary Pi load (Penido & Alon 2012). 
Furthermore, a low pH caused by metabolic acidosis directly inhibits Npt2a (Nowik et al. 
2008).  
 
Sodium-dependent Pi transporter 2c (Npt2c) is present only at one segment (S1) of the 
proximal tubule (Nowik et al. 2008), and accounts for ~30% of Pi reabsorption in mice 
(Tenenhouse et al. 2003). In humans, however, the contribution of the Npt2c to renal Pi 
reabsorption and Pi homeostasis seems to be more important than in mice Biber et al. 
2009). Npt2c shows a preference for divalent Pi (HPO42-), with a stoichiometry of 2 Na 
ions: 1 phosphate (Marks et al. 2010). Dietary Pi decreases expression of Npt2c, but the 
response is slower than that of Npt2a (Segawa et al. 2005). FGF-23 (Segawa et al. 2003) 
and magnesium (Thumfart et al. 2008) increase Npt2c expression, whereas the role of 
PTH in Npt2c regulation is less clear (Marks et al. 2010).  
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In the absence of type II transporters, there is still residual renal Pi reabsorption (Segawa 
et al. 2009), suggesting a role for other Pi transporters. Of type III transporters, Pit2 has 
been localized in the kidney in the S1 segment of the proximal tubule under normal Pi 
intake, while dietary Pi restriction induces expression of Pit2 protein in all segments of the 
proximal tubule (Breusegem et al. 2009). Pit2 preferentially carries monovalent Pi (H2PO4-
), and it transports it with a stoichiometry of 2 Na ions: 1 phosphate (Marks et al. 2010). 
Similar to Npt2c, Pit2 adapts to changes in dietary Pi content more slowly than Npt2a. 
Furthermore, dietary K deficiency and FGF-23 decrease and metabolic acidosis increases 
renal Pit2 protein levels. Still, the role and importance of type III transporters in renal Pi 
handling under different conditions remain obscure. The tubular reabsorption of Pi is 
depicted in Figure 2. 
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Figure 2 Pi reabsorption in the proximal tubule cell (modified from Carpenter 2010). Three 
different Pi transporters (Npt2a, Npt2c, Pit-2) carry Pi in the cell. 
Several other hormonal factors affect renal Pi excretion in addition to PTH and FGF-23. 
Insulin, growth hormone, and thyroid hormone increase Pi reabsorption by increasing Na-
Pi cotransport (Penido & Alon 2012). Calcitonin, glucocorticoids, and phosphatonins 
decrease renal reabsorption. Factors affecting Pi absorption or reabsorption are 
summarized in Table 3.  
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Table 3. Factors influencing phosphate absorption or reabsorption in the intestine and 
kidney. Adapted from Berndt and Kumar (2009). 
Intestine Kidney 
Factors that increase Pi absorption 
1. Reduced dietary intake of P 
2. Elevated serum 1,25-
dihydroxyvitamin D 
Factors that increase Pi reabsorption 
1. Phosphate depletion 
2. Parathyroidectomy 
3. 1,25-dihydroxyvitamin D 
4. Volume contraction 
5. Hypocalcemia 
6. Hypocapnia 
Factors that reduce Pi absorption 
1. Reduced serum 1,25-
dihydroxyvitamin D 
2. Elevated concentrations of Ca salts 
in intestinal lumen 
3. MEPE 
Factors that reduce Pi reabsorption 
1. Pi loading 
2. PTH and cyclic AMP 
3. Volume expansion 
4. Hypercalcemia 
5. Carbonic anhydrase inhibitors 
6. Dopamine 
7. Glucose and alanine 
8. Acid-base disturbances 
9. Increased bicarbonate 
10. Hypercapnia 
11. Metabolic inhibitors 
12. Arsenate 
13. FGF-23 
14. sFRP-4 
15. MEPE 
16. FGF-7  
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2.3.4 Hormones involved in phosphate homeostasis 
2.3.4.1 Parathyroid hormone 
The primary function of PTH is to tightly regulate serum Ca concentration. Hypocalcemia 
stimulates parathyroid glands to produce and release the hormone. PTH increases 
expression of 25(OH)D 1α-hydroxylase in the kidney, resulting in increased production of 
calcitriol, and consequently, increased Ca and Pi absorption in the intestine. The increase 
in Pi absorption is mediated by the increase in Npt2b (see Section 2.3.2). PTH also 
enhances renal Ca reabsorption and reduces renal Pi reabsorption by reducing expression 
of Npt2a and possibly Npt2c (see Section 2.3.3). In bone, PTH increases the release of Ca 
and Pi into the extracellular fluid by stimulating osteoclastic bone resorption. As a result, 
the combined effects of efflux of Ca from bone, conservation of Ca by the kidney, and 
increased dietary absorption of Ca restores serum Ca to normal. The increased Pi efflux 
from bone and influx from the gastrointestinal tract is balanced by PTH effects to decrease 
renal tubular Pi reabsorption to maintain neutral Pi balance. 
 
In addition to hypocalcemia, also elevation of serum Pi stimulates PTH secretion both 
directly and indirectly. The indirect mechanism of Pi to PTH secretion through lowering 
serum Ca concentration has been known for decades (Reiss et al. 1970). The decrease in 
serum Ca by dietary Pi is attributed to the formation of calcium phosphate complexes in 
the blood (Sax 2001). The direct effect of Pi on parathyroid glands both in vitro (Almaden 
et al. 1998) and in vivo (Estepa et al. 1999) was discovered more recently.  
2.3.4.2 Calcitriol 
Production of calcitriol from its precursor 25-hydroxyvitamin D by 1-α-hydroxylation in 
the kidney is tightly regulated. It is induced by PTH and decreased serum Ca and Pi 
concentrations and suppressed by FGF-23 and increased serum Ca and Pi concentrations. 
In addition, two other phosphatonins, fibroblast growth factor 7 (FGF-7) and secreted 
frizzled-related protein-4 (sFRP-4), appear to inhibit synthesis of calcitriol (Bergwitz & 
Jüppner 2011). FGF-23 and calcitriol also increase conversion of 25-OH-vitamin D and 
calcitriol into inactive metabolites.  
 
Calcitriol has both direct and indirect effects on Pi metabolism. Calcitriol affects serum Pi 
directly by increasing its intestinal absorption, but also indirectly by increasing its tubular 
reabsorption through suppressing PTH. The opposing effects of PTH and calcitriol on the 
kidney and the intestine, respectively, balance serum Pi concentration while preserving Ca 
ion homeostasis (Penido & Alon 2012).  
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2.3.4.3 Fibroblast growth factor 23 
Traditionally, the PTH-vitamin D axis described above has provided the basis for the 
understanding of bone and mineral homeostasis. However, discovery of FGF-23 has led to 
finding a bone-kidney axis regulating principally Pi, vitamin D metabolism, and 
mineralization of bone (Martin et al. 2012). This hormonal cascade links bone to several 
other organ functions through a complex endocrine network integrated with the PTH-
vitamin D axis. FGF-23 is mainly produced by osteoblasts and osteocytes (Yoshiko et al. 
2007), even though it is also expressed by salivary glands, by the stomach, and at much 
lower concentrations by other tissues such as skeletal muscle, brain, mammary gland, 
liver, and heart (Martin et al. 2012).  
 
Calcitriol is the most important systemic regulator of FGF-23; it seems to directly 
stimulate FGF-23 production in bone (Liu et al. 2006). In contrast, the effect of Pi on 
FGF-23 is not completely clear. In patients with renal failure, FGF-23 concentrations are 
elevated, and the degree of elevation correlates with the degree of hyperphosphatemia 
(Weber et al. 2003). However, in healthy humans, dietary Pi may not affect FGF-23 
secretion (Larsson et al. 2003), at least not acutely (Nishida et al. 2006, Lamberg-Allardt 
et al., unpublished results). On the other hand, dietary Pi intake has been shown to regulate 
serum FGF-23 concentration in longer-term studies on healthy individuals (Ferrari et al. 
2005, Antoniucci et al. 2006, Burnett et al. 2006). Pi load, rather than serum 
concentration, has been speculated to regulate FGF-23, as FGF-23 may vary in animals 
and patients without any changes in serum Pi (see Martin et al. 2012). Furthermore, Martin 
et al. (2012) suggest that Pi only has indirect effects on FGF-23 production, mediated 
through the effects of Pi on extracellular matrix mineralization.  
 
Another systemic regulator of FGF-23 production is leptin, a hormone secreted by white 
adipose tissue to control energy intake and expenditure and bone homeostasis. Leptin 
stimulates FGF-23 production in bone (Tsuji et al. 2010). Similarly, oestrogens may be a 
potent stimulator for FGF-23 (Carrillo-Lopez et al. 2009). FGF-23 expression is 
downregulated, through yet unknown mechanisms, by phosphate regulating gene with 
homologies to endopeptidases on the X chromosome (PHEX) and dentin matrix protein 1 
(DMP1), both of which are expressed by osteoblasts and osteocytes (Martin et al. 2012). 
 
FGF-23 is secreted in the systemic circulation. In its target tissues, FGF-23 binds to and 
activates FGF receptors when its essential co-factor Klotho is present (Penido & Alon 
2012). Klotho is a transmembrane protein highly expressed in the kidney and, to a lesser 
extent, in the parathyroid glands and brain. Klotho forms complexes with FGF receptors 
and increases their affinity for FGF-23.  Hence, whether Klotho is present or absent 
dictates which tissues will respond to FGF-23. Abnormalities in either FGF-23 or Klotho 
production or function underlie many inherited and acquired disorders of phosphate 
homeostasis (Shaikh et al. 2008, Martin et al. 2012). 
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FGF-23 acts in the renal proximal tubule to reduce the expression of Npt2a and Npt2c, 
leading to decreased Pi reabsorption (Saito et al. 2003). FGF-23 also reduces the 
production of calcitriol and increases its catabolism to inactive metabolites by inhibiting 
the activity of 1-α hydroxylase and stimulating that of 24-hydroxylase (Shimada et al. 
2004). Through the reduction in serum calcitriol, FGF-23 further reduces the intestinal 
absorption of Pi (Saito et al. 2003). FGF-23 may also inhibit PTH secretion (Ben-Dov et 
al. 2007). In summary, the main function of FGF-23 and the reason for its predominant 
expression in bone are to protect the cells from the toxic effects of excess Pi and calcitriol 
(Martin et al. 2012). More specifically, FGF-23 acts as a counter-regulatory hormone for 
calcitriol and coordinates renal Pi handling to match bone mineralization. Still, there is 
much to be discovered about FGF-23 regulation and function such as the interrelationships 
between bone remodeling, PTH, vitamin D, Klotho, and FGF-23. The current 
understanding of the regulation of P homeostasis is shown in Figure 3. 
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Figure 3 Regulation of phosphorus homeostasis (adapted from Lien 2013).  
2.3.4.4 Other   
To date, three phosphatonins in addition to FGF-23 have been identified: secreted frizzled 
related protein-4 (sFRP-4), matrix extracellular phosphoglycoprotein (MEPE), and 
fibroblast growth factor 7 (FGF-7) (Shaikh et al. 2008). Like FGF-23, sFRP-4 decreases 
renal Pi reabsorption by reducing Npt2a in renal proximal tubules and suppresses the 
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synthesis of calcitriol. MEPE increases the fractional excretion of Pi, inhibits bone 
formation in vitro, and inhibits intestinal Npt2b expression (see Section 2.3.2), but does 
not inhibit calcitriol formation. FGF-7 is able to inhibit Npt transport in animal kidney 
cells, but like MEPE does not influence the synthesis of calcitriol (Carpenter et al. 2005). 
Renal Pi handling is also affected by other systemic hormones such as insulin, growth and 
thyroid hormone, calcitonin, and glucocorticoids (see Section 2.3.2). 
2.4 Bone metabolism 
Bone is a specialized connective tissue, which together with cartilage makes up the 
skeletal system. Bone is constituted of bone cells (2-5% of volume) and the extracellular 
matrix (95-98% of volume), the latter consisting of mineral-covered protein matrix 
(Heaney 1999). The protein matrix is formed of collagen fibres (type I, 90% of total 
protein) and non-collagenous proteins. The mineral content of bone is mostly 
hydroxyapatite [Ca10(PO4)6(OH)2]. Osteocytes, i.e. bone cells, are found embedded deep 
within the bone in small lacunae. Osteocytes have numerous long cell processes that form 
a network of thin canaliculi permeating the entire bone matrix. Due to this architecture, all 
normal bone is in contact with living cells.  
 
The calcified bone matrix is not metabolically inert. Most of the bone tissue turnover 
occurs at the bone surfaces, particularly at the endosteal surface where it interfaces with 
bone marrow. Two types of bone tissue exist: cortical bone, which is mainly found in the 
diaphysis of long bones, and trabecular bone, which exists more commonly in the 
metaphysis and epiphysis of long bones and vertebrae (Clarke 2008). Cortical bone is 
typically less metabolically active than trabecular bone. 
  
Osteoblasts are the bone lining cells that lay down bone by synthesizing, depositing, and 
orienting the proteins of the matrix, then initiating changes for matrix mineralization 
(Heaney 1999). Osteoblasts secrete alkaline phosphatase to hydrolyse organic Pi 
compounds, which would otherwise inhibit mineralization. After stopping matrix 
synthesis, osteoblasts become osteocytes. Osteoclasts are cells that resorb bone by 
secreting hydrogen ions and proteolytic enzymes, such as cathepsin K, into the resorption 
compartment beneath them. After a cycle of resorption, osteoclasts undergo apoptosis, 
leaving their excavation to be refilled by osteoblasts. The process of removal of old bone, 
replacing it with newly synthesized proteinaceous matrix, and subsequent mineralization 
of the matrix to form new bone, is called remodelling. By remodelling, bone is renewed to 
maintain bone strength and mineral homeostasis. Modelling is a similar process to 
remodelling, except that during modelling the new bone is laid down at a location different 
from the site of resorption, and bone formation and resorption are not tightly coupled 
(Clarke 2008). By modelling, bones change their shape during growth. 
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2.4.1 Regulation of bone metabolism 
Both systemic and local regulators affect bone cell function. Of systemic regulators of 
bone metabolism, the most important hormone is PTH, which stimulates bone formation 
when given intermittently and bone resorption when secreted continuously (Hock & Gera 
1992). By stimulating absorption of Ca and P, calcitriol maintains adequate serum 
concentrations of these minerals, allowing passive mineralization of the unmineralized 
bone matrix. Serum calcitriol also promotes differentiation of osteoblasts and stimulates 
the expression of alkaline phosphatase and several cytokines (Clarke 2008). Calcitonin 
inhibits the function of osteoclasts only at pharmacologic doses (Hadjidakis & 
Androulakis 2006). Growth hormone is essential for skeletal growth, affecting both bone 
formation and resorption. Glucocorticoids have stimulatory as well as inhibitory effects on 
bone cells. However, glucocorticoid treatment is associated with increased bone resorption 
and risk of ostoporosis (Canalis et al. 2007). Thyroid hormones stimulate both bone 
resorption and formation, causing increased bone turnover in hyperthyroidism (Hadjidakis 
& Androulakis 2006). Oestrogens affect bone cells through several mechanisms, resulting 
in prevention of osteoclast formation and inducing their apoptosis, but also stimulating 
osteoblast proliferation and increasing their life span. Hence, inadequate oestrogen is 
associated with increased osteoclastic bone resorption. Androgens have similar effects on 
bone. In addition, they are essential in bone growth. 
 
FGF-23 affects bone indirectly through its effects on calcitriol and PTH. Both under- and 
over-expression of FGF-23 have been shown to result in impairments in bone metabolism 
(Sitara et al. 2004, Liu et al. 2006b). Despite reported Klotho absence from mineralized 
tissues, there is debate regarding whether FGF-23 also affects bone directly (Martin et al. 
2012). Results from animal models and cell studies suggest that FGF-23 inhibits 
mineralization in bone directly, independent of Pi homeostasis (Sitara et al. 2008, 
Shalhoub et al. 2011). 
 
Of local regulators of bone cells, osteoprotegerin (OPG)/receptor activator of nuclear 
factor-κB ligand (RANKL)/receptor activator of nuclear factor-κB (RANK) system is vital 
in the control of osteoclastogenesis and bone remodelling in general (Hadjidakis & 
Androulakis 2006). Preosteoblastic/stromal cells express RANKL, which interacts with 
RANK. The RANKL/RANK interaction results in osteoclastogenesis and promotion of 
osteoclast survival. OPG, a glycoprotein mainly produced by cells of the osteoblast 
lineage, inhibits the entire system by blocking the effects of RANKL. OPG and RANKL 
may act as the mediators for the stimulatory or inhibitory effects of a variety of systemic 
hormones, growth factors, and cytokines on osteoclastogenesis. For example, PTH 
increases the production of RANKL and decreases that of OPG.  
 
Other central local factors affecting bone metabolism are macrophage colony-stimulating 
factor (M-CSF), which appears to be necessary for osteoclast development, and several 
cytokines, such as tumour necrosis factor α (TNF-α) and interleukin 10 (IL-10), which 
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stimulate M-CSF production and increase RANKL expression (Hadjidakis & Androulakis 
2006). Interleukin 6 (IL-6), another cytokine secreted by osteoblasts, osteoclasts, and 
stromal cells, stimulates osteoclastic bone resorption and osteoblast generation in 
conditions of high bone turnover.  
2.4.1 Markers of bone metabolism 
Currently available markers of bone turnover include both enzymes and non-enzymatic 
peptides derived from cellular and non-cellular compartments of bone (Seibel 2005). They 
are usually classified as markers of bone formation or bone resorption. This distinction is 
not, however, absolute; some markers, at least partly, reflect both bone formation and 
resorption (e.g. certain osteocalcin fragments).  
 
Markers of bone formation are products of active osteoblasts considered to reflect different 
aspects of osteoblast function and bone formation (Seibel 2005). All bone formation 
markers are measured in serum or plasma. Serum total alkaline phosphatase (AP) is the 
most widely used marker of bone metabolism due to its simple and inexpensive detection 
methods. The exact function of the enzyme is unknown. As various tissues produce AP, 
techniques for analysing the bone-specific isoform of AP (BALP) have been developed, 
even though a good correlation between BALP and total AP has been found in healthy 
adults (Woitge et al. 1996). Another commonly used bone formation marker is osteocalcin 
(OC), which is a hydroxyapatite-binding protein exclusively synthesized by osteoblasts, 
odontoblasts, and hypertrophic chondrocytes (Seibel 2005). OC is considered a specific 
marker of osteoblast function, and newer assays measuring its mid-molecule eliminate in 
part the problem of pre-analytical instability. Osteoblasts synthesize type I collagen from 
its precursor molecules characterized by the amino-terminal propeptide (PINP) and the 
carboxy-terminal propeptide (PICP).  These peptides are also used as markers of bone 
formation. 
 
Many bone resorption markers are degradation products of bone collagen (Seibel 2005). 
However, non-collagenous proteins, such as bone sialoprotein, and osteoclast-derived 
enzymes, such as cathepsin K and L, have recently been investigated as markers of bone 
metabolism. Pyridinolines (Pyr) and deoxypyridinolines (DPyr) are collagen crosslink 
components that are proteolytically broken down during bone resorption. Pyr and DPyr are 
highly specific to skeletal tissues, and they can be measured in serum or urine samples. 
Carboxy- and amino-terminal telopeptides of type I collagen (CTx and NTx, respectively) 
measured either in serum or urine are also used as bone resorption markers. Tartrate-
resistant acid phosphatase (TRACP) is an enzyme with two known subforms, 5a and 5b, 
the latter of which is characteristic of osteoclasts. TRACP can be measured in serum or 
plasma. 
 
  
 
42
The problem regarding the use of bone markers is the large within-subject variability 
(Seibel 2005). To deal with this variability, diurnal and seasonal variation, the age and sex 
of the subject, and menstrual cycle in premenopausal women should be taken into account 
when interpreting the results. In addition, standardized sampling and sample handling are 
required to obtain reliable results. It should also be noted that abnormal kidney function 
affects concentrations of bone markers. 
2.5 Disorders involving phosphorus  
2.5.1 Chronic kidney disease 
Chronic kidney disease (CKD) is the progressive loss of renal function due to an 
irreversible and progressive glomerular, tubular, or interstitial disease (Edwards 2002).  
CKD is classified into stages 1-5 based on the presence or absence of biomarkers in blood 
or urine and the glomerular filtration rate (GFR) (Table 4, National Kidney Foundation 
2002). GFR is usually estimated from serum creatinine by using either the Cockroft-Gault 
or the MDRD (Modification of Diet in Renal Disease) formula. Treatment in the early 
stages may prevent or delay the progression of CKD, but early detection is often difficult 
due to the asymptomatic nature of the disease. Stage 5, defined as end-stage renal disease 
(ESRD), often requires renal replacement therapy, i.e. dialysis or transplantation.  
 
 
Based on epidemiological studies, the median prevalence of CKD is ca. 7% in persons 
aged 30 years or older, varying depending on ethnic background (Zhang & Rothenbacher 
2008). Independently of age, hypertension and obesity are associated with an increased 
prevalence of CKD (Otero et al. 2010). Other risk factors of CKD include diabetes, 
dyslipidemia, and smoking (Foley et al. 2005, Kronborg et al. 2008, Otero et al. 2010). 
CKD is a risk factor for all-cause mortality, cardiovascular disease, and other 
comorbidities, and it substantially lowers the self-reported quality of life (National Kidney 
Foundation 2002). Furthermore, treatment of CKD and its complications is a tremendous 
economic burden globally (Jha et al. 2012).  
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Table 4. Stages of chronic kidney disease. 
Stage Description GFR (ml/min/1.73 m2) 
1 Kidney damage with normal or ↑ GFR  ≥90 
2 Kidney damage with mild ↓ GFR 60-89 
3 Moderate ↓ GFR 30-59 
4 Severe ↓ GFR 15-29 
5 Kidney failure <15 (or dialysis) 
  
Patients with CKD progressively lose the ability to excrete P (Shroff 2012).  Decreased P 
excretion is initially compensated by increased PTH and FGF-23 secretion. As renal 
function declines, increasingly higher levels of PTH are needed to maintain Pi 
homeostasis. In the advanced stages of renal disease, the elevated levels of PTH are unable 
to maintain normal S-Pi concentrations and hyperphosphatemia becomes evident. 
Hyperphosphatemia is associated with dysregulation in Ca, PTH, and vitamin D 
homeostasis. These changes can result in bone demineralization and ectopic soft tissue 
calcification, leading to the complex of CKD – mineral and bone disorder (CKD-MBD) 
(Moe et al. 2006). The biochemical changes in CKD-MBD are summarized in Figure 3.   
 
Figure 4 Biochemical changes in CKD-MBD (adapted from Keronen et al. 2012). 
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Vascular calcification in CKD patients occurs in both the intima and media layers of the 
vessel wall. Intimal deposition is associated with atherosclerotic plaques, while medial 
deposition is associated with vascular stiffening and arteriosclerosis. Vascular calcification 
largely explains the early cardiovascular morbidity and mortality of CKD patients (Blacher 
et al. 2001), and it occurs decades earlier than in the general population (Goodman et al. 
2000). In a longitudinal cohort study, higher serum P levels were associated with a greater 
risk for end-stage renal disease and mortality in subject with normal kidney function (Sim 
et al. 2013), indicating that dietary P could play a role also in the aetiology of CKD. Early 
treatment of Pi retention or hyperphosphatemia may prevent or slow the development of 
CKD-MBD (Martin & González 2011). Pi retention is treated with dietary P restriction, 
limiting intestinal P absorption by using oral P binders (usually Ca acetate or Ca 
carbonate) and, at stage 5, dialysis. However, the efficacy of current P binders is limited, 
and dialysis is not sufficient to maintain a normal serum Pi concentration in a patient 
eating an average diet (Winger et al. 2011). Therefore, depending on the protein need of 
the patient, the recommended intake of P for a CKD patient is <800-1000 mg/d (National 
Kidney Foundation 2003, Finnish Kidney and Liver Association 2009). 
 
Dietary P restriction is implemented by preferring products with the lowest possible P 
contents among both animal and plant protein sources and by avoiding P additive-
containing foods (Finnish Kidney and Liver Association 2009, Kalantar-Zadeh et al. 
2010). When dietary P is restricted, also protein intake is reduced, as protein-rich foods are 
major P sources. At CKD stages 2-4, protein restriction (0.6-0.8 g/kg/d) is beneficial, as a 
low dietary protein intake slows the progression of the disease (Fouque & Laville 2009). 
However, the protein need for ESRD patients in dialysis is higher (ca. 1.2 g/kg/d) because 
dialysis removes not only P, but also protein and amino acids from the blood (National 
Kidney Foundation 2003, Finnish Kidney and Liver Association 2009). To facilitate 
implementing appropriate protein and P intakes in CKD, a ratio of P (mg) to protein (g) 
may be a more suitable measure than the P content of a food alone (Kalantar-Zadeh et al. 
2010). The recommended P-to-protein ratio for CKD patients is ≤ 15 (Finnish Kidney and 
Liver Association 2009). Still, for better outcomes of the nutritional care of CKD patients, 
a need for better knowledge of P bioavailability from different foods, more accurate 
reporting of P contents of foods by manufacturers, and development of lower P foods by 
the food industry exists (Kalantar-Zadeh et al. 2010, Winger et al. 2011). 
2.5.2 Osteoporosis and bone health 
Osteoporosis is a systemic skeletal disease characterized by low bone mineral density 
(BMD) and microarchitectural deterioration of bone tissue, which result in increased bone 
fragility and fractures (WHO 2003). BMD can be measured by dual x-ray absorptiometry 
(DXA), and osteoporosis is defined as BMD 2.5 SD below the average of a young adult. 
However, early osteoporosis is usually asymptomatic and remains undiagnosed until 
fractures occur. Osteoporotic fractures most commonly occur in the spine, hip, or wrist, 
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resulting in loss of mobility and autonomy and poorer quality of life. Furthermore, hip and 
spine fractures increase 12-month mortality risk due to hospitalization and chronic 
immobilization (Center et al. 1999).  
 
Concern about high P intake and its role in the development of osteoporosis originates 
from animal studies. Development of secondary hyperparathyroidism with bone loss has 
been consistently documented in several species of animals fed a P-rich diet (Sie et al. 
1974, Cook et al. 1983, for review, see Calvo & Park 1996). More recently, a high P 
intake has been observed to impair growth and result in poorer bone quality in rats 
(Huttunen et al. 2007). A rise in serum PTH concentration after oral Pi load has also been 
found in humans (Reiss et al. 1970, Brixen et al. 1992, Kärkkäinen & Lamberg-Allardt 
1996, Kemi et al. 2006), which, in the long run, increases bone resorption. In a short-term 
controlled study, the effect of Pi on S-PTH has been shown to be dose-dependent (Kemi et 
al. 2006). However, results of several other experimental human studies on dietary P are 
confounded by not controlling for Ca intake (Silverberg et al. 1986, Silverberg et al. 1989, 
Brixen et al. 1992) or by simultaneous changes in both Ca and P intakes (Calvo et al. 
1988, Calvo et al. 1990). Still, cross-sectional studies support the findings of P on PTH 
(Kemi et al. 2009, Kemi et al. 2010). Dietary P seems to affect PTH secretion more 
strongly in women than in men (Calvo et al. 1988, Whybro et al. 1988), and in older 
subjects than in younger subjects (Silverberg et al. 1989, Renier et al. 1992). In addition to 
increased PTH secretion, dietary P load decreases serum calcitriol concentration, as 
observed in healthy men (Portale et al. 1986) and in young (Kemi et al. 2006) and 
postmenopausal women (Silverberg et al. 1989). 
 
Divergent results on effects of P on markers of bone turnover have been reported. In the 
short-term study of Kärkkäinen & Lamberg-Allardt (1996), a single dose of 1500 mg of P 
decreased markers of bone formation (BALP and PICP), but did not affect markers of 
bone resorption. In the similar study of Kemi et al. (2006), both 750 mg and 1500 mg 
doses of P decreased S-BALP, and the 1500 mg P dose increased urinary NTx, indicating 
increased bone resorption and decreased bone formation. In most other studies, changes in 
markers of bone metabolism were not found (Calvo et al. 1990, Brixen et al. 1992, 
Whybro et al. 1998, Grimm et al. 2001). In addition to differing Ca and P intakes and 
study designs, the power of the studies may have been too low to detect differences in the 
bone markers. The current more sensitive markers of bone metabolism could more easily 
disclose changes with smaller numbers of subjects. 
 
Some studies have examined the effects of dietary P on BMD. In cross-sectional studies of 
postmenopausal (Tylavsky & Anderson 1988) and young women (Metz et al. 1993), radial 
BMD was negatively associated with P intake. Moreover, a high dietary Ca:P ratio (1.2-
1.4) was related to higher total body BMC and BMD in multiple regression analyses in a 
cross-sectional study of young women (Teegarden et al. 1998). An association between 
low dietary Ca:P ratio and low BMD has also been observed in perimenopausal women 
(Brot et al. 1999). As cola drinks contain phosphoric acid, and hence, are a Ca-free P 
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source, their relationship to bone health has been investigated in some studies. In the 
Framingham Osteoporosis Study, a dose-response relationship was observed between the 
amount of cola (also decaffeinated and diet cola) consumed and BMD in 29- to 83-year-
old women, but not in men (Tucker et al. 2006). The inverse association was not seen with 
use of non-cola soft drinks, which suggests phosphoric acid as the factor behind the results 
concerning cola beverages. Similar results were reported in adolescent girls, in whom 
higher intakes of carbonated soft drinks were associated with lower heel BMD 
(McGartland et al. 2003). Such an association was not found in boys. Earlier, however, no 
association was observed between cola drink consumption and BMD in women aged 44-
98 years (Kim et al. 1997). 
 
Data on P intake and fracture risk are scarce. In a follow-up study among middle-aged and 
elderly men, the lowest P intake quintile was associated with an increased fracture risk 
compared with subjects in the second quintile (Elmståhl et al. 1998). Greater risk of 
fractures has been found in former female athletes (Wyshak et al. 1989), and in adolescent 
girls (Wyshak & Frisch 1994, Wyshak 2000) who consumed carbonated beverages 
compared with those who did not. However, the study of Wyshak (2000) has been 
criticized for methodological problems (Williams 2001). Furthermore, according to 
Fitzpatrick & Heaney (2003), the association between soft drinks and BMD or fractures is 
more likely due to displacement of milk consumption than to a direct effect of soft drink 
components. The P contents of cola and other soft drinks are smaller than those of several 
other beverages, including milk, which supports this opinion.   
 
To conclude, the data especially from human studies on P intake and bone health are 
inconsistent and insufficient to draw definite conclusions. More population-based and 
controlled long-term intervention studies on skeletal variables and fractures are needed to 
address the effect of high P intake on bone.     
2.5.3 Cardiovascular disease 
The role of P in the vascular component of CKD is well established. In recent studies, 
higher serum Pi levels even within the normal range have been associated with increased 
risks of cardiovascular events in healthy populations with intact kidney function (Foley et 
al. 2008, Dhingra et al. 2008, Foley et al. 2009, Larsson et al. 2010). Furthermore, higher 
serum Pi levels have been shown to be associated with risk of death and cardiovascular 
events in adults with prior myocardial infarction (Tonelli et al. 2005). Similar results in 
cardiovascular mortality have been found in type 2 diabetics (Chonchol et al. 2009). On 
the other hand, in a case-control study, serum Pi levels were not associated with the 
development of incident coronary heart disease in men without CKD (Taylor et al. 2011).  
 
Several mechanisms may explain the association between S-Pi increases and 
cardiovascular events. Firstly, abnormal Pi handling may contribute to the initiation and/or 
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progression of vascular calcification by multiple mechanisms. Phosphate may induce 
phenotypic changes in vascular smooth muscle cells (VSMCs), causing them to transform 
from a contractile phenotype to an osteochondrogenic phenotype (Kendrick & Chonchol 
2011). Furthermore, Pi has been hypothesized to induce apoptosis of VSMCs, which could 
accelerate the calcification process. Elevated Pi concentrations may also decrease the 
differentiation of monocytes/macrophages of the vessel wall into osteoclast-like cells. It 
has been speculated that this reduction in osteoclast activity may be an additional way that 
elevated Pi levels result in vascular calcification, as osteoclast-like cells prevent mineral 
deposition in the vasculature. High serum FGF-23 concentrations are linked to death and 
cardiovascular events by unknown mechanisms. Hence, Pi-mediated elevation of FGF-23 
has been suggested to be another factor affecting vascular calcification. In addition, Pi may 
be related to vascular calcification through Klotho, which may inhibit calcification directly 
by affecting VSMCs, and indirectly by controlling S-Pi through its interaction with FGF-
23. In healthy human subjects, an oral Pi supplement that increased S-Pi to the upper limit 
of the normal range was associated with a transient reduction in endothelium-dependent 
brachial artery dilation, suggesting that acute postprandial hyperphosphatemia mediates 
endothelial dysfunction (Shuto et al. 2009). A recent rat study provided further support for 
the role of Pi in endothelial function, as dietary P restriction ameliorated endothelial 
dysfunction in kidney diseased rats (Van et al. 2012).  
 
The associations discussed above are between cardiovascular events and S-Pi rather than 
dietary intake, and dietary P sources may complicate these findings (Ellam & Chico 2012). 
Furthermore, there is a need to understand the contribution of each component of the Pi 
regulatory axis (PTH, FGF-23, calcitriol) to any causative mechanisms of atherogenesis in 
order to optimize the whole axis. The question remains as to whether reducing S-Pi 
prevents or reverses cardiovascular risk factors.     
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3 Aims of the study 
The objective of this thesis was to study total and in vitro digestible P content (TP and DP, 
respectively) of foods and the effects of different P sources on mineral metabolism of 
healthy subjects. 
 
Specific research questions were as follows: 
 
Study I: Are there differences in TP and DP content of selected commonly used plant 
foods and beverages? 
 
Study II: Are there differences in TP and DP content of selected commonly used meat and 
milk products? 
 
Study III: Do different P sources affect markers of P, Ca, and bone metabolism differently 
in healthy young females?  
 
Study IV: Do mono- and polyphosphates affect markers of P and Ca metabolism 
differently in healthy young females?  
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4 Subjects and methods 
4.1 Food studies (Studies I and II) 
4.1.1 Foods chosen for phosphorus analyses 
Foods considered relevant as P sources were chosen for analysis. Meat, milk, grains, and 
legumes are important P and protein sources; thus, products from these food groups were 
analysed. In addition, foods containing P additives, i.e. cola beverages, processed cheeses, 
and meats, were analysed. To clarify P contents of similar products, several labels among 
processed meats, cola beverages, cheeses, and breads were evaluated.  
 
To improve representativeness of the analyses, we focused on the nationally most popular 
products in each food category. Market shares of the products were found on the basis of a 
substudy of the national dietary survey FINDIET (Reinivuo et al. 2010).  The main aim of 
the substudy was to investigate the market shares of food products. For this purpose, a 
subsample (50%) of the participants (n=1025) of the FINDIET Study filled in a 5-day 
product purchase diary to investigate the purchase and use of voluntarily fortified foods. A 
total of 930 subjects (91%) returned the diary, 918 (90%) of which were of acceptable 
quality. Each food item was assigned a food identifier from the Finnish Food Composition 
Database (Fineli), enabling data classification. Market shares of each product were 
calculated by dividing the total amount (kg) of purchased product by the total amount of 
purchased food in the same food class. 
 
Two to seven of the most popular trademarks (highest market shares) were pooled for each 
sample item. The leading trademark in each sample category was analysed as such. The 
chosen sample items were purchased from grocery stores in the Helsinki area. The number 
of purchased trademarks was twice the proportion of that item in the pool (40% in the pool 
corresponding to 8 subsamples). The minimum was two subsamples for each pooled 
category per trademark. The samples were homogenized in a blender, packed into 
polyethylene bags, and stored at -20ºC until analysis. 
 
We hypothesized that the use of P-containing additives increases both total and in vitro 
digestible P content (TP and DP, respectively) of the food compared with products 
prepared without P additives. Furthermore, we hypothesized that the proportion of DP to 
TP is lower in plant-based P additive-free products than in products of animal origin. 
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4.1.2 Analysis of total phosphorus in foods 
The food sample (0.5 g) was digested in a microwave oven with 10 ml of concentrated 
nitric acid. The sample was transferred to a 50-ml volumetric flask with purified water, 
and the content of P was analysed with ICP-OES. The quantitation was performed by 
using an external calibration curve with five different concentrations. P was analysed 
radially with wavelengths of 177.4, 178.2, 178.7, and 213.6 nm. The results were 
calculated as a mean. All treatments of the samples were with five replicates. The fat was 
removed from samples if the fat content was more than 6-8%. Petroleum ether (200 ml, 
bp: 60ºC to 71ºC) was added and the suspension was agitated with a magnetic stirrer at 
room temperature for 15 min. The solvent was filtered and the sample was air-dried at 
room temperature overnight. 
 
The accuracy and precision of the total P (TP) content of the samples were tested using 
NBS 1567a wheat flour reference material and one in-house reference material (flour I) in 
every P determination batch. TP contents of analysed foods were calculated per 100 g of 
the product. TP-to-protein ratios (mg/g) were calculated. Protein and sodium contents of 
foods were taken from either food labels or the food composition database. 
 
4.1.3 Analysis of in vitro digestible phosphorus in foods 
The samples were treated according to the method described by Asp et al. (1983) for 
dietary fibre, with some modifications for the determination of DP (Ekholm et al. 2000). 
In this method, starch and proteins of the sample were digested enzymatically, in principle, 
in the same way as in the alimentary canal. The samples were then dialysed and DP was 
analysed from the dialysate by inductively coupled plasma optical emission spectrometry 
(ICP-OES, Thermo Scientific iCAP 6000 Series ICP Spectrometer, Waltham, MA, USA). 
The insoluble mineral bound by food components remained in the dialysis residue. 
 
The homogenized and ground sample was weighed into a 100-ml flask. In all, 50 ml of 
purified water (MilliQ) was added, and the starch was gelatinized by incubating the 
sample in a boiling water bath for 15 min. Then 0.5 ml of the thermal stabile amylase 
enzyme (Termamyl 300 L, Novo Nordisk A/S Bagsvaerd, Denmark) was added, and the 
mixture was further incubated in the boiling water bath for 1 h 45 min to hydrolyse the 
starch. The amount of amylase enzyme was kept as low as possible to minimize 
contamination by Ca and P originating from the enzyme. The pH of the reaction mixture 
was then adjusted to 1.5 with 1 M HCl. After addition of 0.5 g of Pepsin (0.7 FIP-U/mg, 
EC 3.4.23.1, Merck, Darmstadt, Germany), the mixture was incubated at 40ºC for 60 min. 
The pH was increased to 6.8 with 1 M NaOH, and 0.5 g of pancreatin enzyme (Sigma 8 X 
3 U.S.P, St. Louis, MO, USA) was added and the sample mixture was kept for an 
additional 60 min at 40ºC. The volume of the samples was adjusted to 100 ml with 
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purified water, and 50 ml of the mixture was dialysed against purified water overnight at 
room temperature. The concentrations of P in the dialysate were determined by ICP-OES 
as described in Section 4.1.2. 
 
The uncertainty of the method in determining the digestibility of P was 7.4%, and it was 
determined using an in-house reference sample (wheat flour) in every analysed batch and 
calculated according to Eurachem (Eurachem/Citac 2000). DP contents of analysed foods 
were calculated per 100 g of the product. The proportions of DP to TP were determined. 
DP-to-protein ratios (mg/g) were calculated.  
4.2 Human studies (Studies III and IV) 
4.2.1 Subjects  
The subjects participating in the studies were healthy 19- to 31-year-old female volunteers 
recruited from the University of Helsinki Viikki campus area. The participants had no 
medications or illnesses known to affect calcium or bone metabolism other than hormonal 
contraceptives. Before the beginning of the study, the subjects kept a 4-day food record, 
for which they received instruction both in writing and verbally. The habitual dietary 
intake of the subjects was calculated with computer-based programs Diet 32 (Aivo 1.2.2.2, 
AIVO Finland Oy, Turku, Finland) (Study III) and Flamingo (version 0.5.6, Helsinki, 
Finland) (Study IV). Background information, such as weight and height of the volunteers, 
was collected with self-reported questionnaires.  
4.2.1.1 Ethical considerations 
The studies were conducted according to the guidelines laid down in the Declaration of 
Helsinki, and all procedures were approved by the Ethics Committee of Public Health and 
Epidemiology in the Hospital Districts of Helsinki and Uusimaa (Study III) and the Ethics 
Committee of the Faculty of Agriculture and Forestry (Study IV). Written informed 
consent was obtained from all subjects prior to their inclusion in the study. Subjects could 
withdraw their participation without a reason at any time. After the study, they were 
provided with the results of their personal nutrient intakes based on the food record. 
4.2.2 Study designs and hypothesis  
The studies were controlled short-term (24-h) studies in which subjects served as their own 
controls. The subjects attended the 24-h sessions at 7-day intervals. To exclude the effect 
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of alcohol on PTH secretion, the subjects were advised not to drink alcohol 24 h before the 
beginning of the study sessions. In addition, the subjects were asked to maintain 
consumption of milk products at their usual level before the study sessions to prevent 
exceptional Ca intakes that could have affected PTH secretion. During the study sessions 
all meals were provided. Except for supper, all meals were eaten at the research unit. The 
meals were prepared from normal foods purchased from local grocery stores, and prepared 
and measured by the same person on each study day. No additional meals or snacks were 
allowed, but water was provided ad libitum. The food composition database (Fineli®) of 
the National Institute for Health and Welfare and manufacturers’ information were used in 
designing the study diets. In addition, the P concentrations of the whole-grains, meats, and 
cheeses used in Study III were analysed at the laboratory of the Finnish Meat Research 
Institute. 
4.2.2.1 Study III 
In Study III, sixteen healthy female volunteers participated in five separate 24-h sessions. 
Before coming to the research unit, subjects fasted overnight. At the control session, both 
Ca and P intakes were low (approximately 250 and 500 mg/day, respectively). During the 
other four sessions P intake was approximately 1500 mg/day, 1000 mg of which was 
obtained from meat, cheese, whole-grains, or a phosphate supplement, respectively. The 
order of the study sessions was randomized. The foods served during P sessions and the 
control session were identical, with the exception of differing P sources. P intake was 
divided evenly between these meals at all sessions. The schedule of a study session is 
summarized in Figure 5. 
   
 
 
Figure 5  Schedule of study days in Study III. 
At the meat session, the main P sources were ham and beef steak, both prepared without P 
additives. At the cheese session, the subjects were served fermented cheese (Edam type, 
17% fat). At the whole-grain session, the main P sources were oatmeal porridge and non-
fermented rye bread. The P supplement was prepared from a mixture of disodium and 
trisodium phosphates (E450 and E451; Six Oy, Helsinki, Finland) and served in a 
refreshment drink. To increase protein intake during the control, whole-grain, and 
supplement sessions, cooked egg white was served to subjects because egg white has a 
high protein but very low phosphorus content. Energy intakes were balanced by using 
different amounts of oil, margarine, sugared and diluted berry juice, berry soups, and 
Blood samples
Meals
Urine collection
Time8:00 10:00 12:00 14:00 16:00 18:00 20:00 . . . . . . 8:00
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canned fruit. The diets during each session contained the same amounts of sodium (3.8 
g/day). The amount of daily protein consumed was similar (82-95 g/day) during all 
sessions other than the meat session, when protein intake was higher (125 g/day) because 
of the high protein content of meat. Likewise, fibre intake was higher (59 g/day) during the 
whole-grain session than during the other sessions (19-21 g/day). The Ca intake during the 
cheese session was high (2044 mg/day). The intakes of selected nutrients during the study 
sessions are presented in Table 5. We hypothesized that depending on differences in P 
absorbability, the P sources have different effects on mineral metabolism.   
 
Table 5.  Intakes of selected nutrients during the study sessions (Study III).    
Variable Control  Meat  Whole 
grains  
Cheese  Supplement 
Energy (MJ)  8.5  8.4  8.4  8.5  8.8  
Protein (g)  82  125  82  88  95  
Carbohydrate (g)  266  237  278  260  289  
Fat (g)  68  60  60  68  59  
Ca (mg)  235  274  352  2044  246  
P (mg)  484  1435  1509  1624  1458  
Na (mg)  3826  3855  3850  3833  3824  
Fibre (g)  20  19  59  21  19  
4.2.2.2 Study IV 
Fourteen healthy female volunteers participated in three separate 24-h sessions. During 
each session the subjects ingested either a monophosphate (MP), polyphosphate (PP) or 
placebo supplement during three meals. The MP supplement contained sodium dihydrogen 
phosphate (NaH2PO4·2H2O, E339, Merck Eurolab, Germany) and the PP supplement 
sodium tripolyphosphate (Na5P3O10, E452, Six Oy, Finland). The Pi and placebo drinks 
were divided into three doses, and served at 08:00, 12:00, and 16:00 hours with meals. The 
schedule of a study session is shown in Figure 6.  
 
Figure 6 Schedule of study days in Study IV. 
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The Pi supplements contained 1500 mg/d P, each dose containing 500 mg of P. The meals 
served during each study session were identical, providing 340 mg of Ca and 500 mg of P.  
Since the Pi supplements also contained Na, the Na intakes were higher during the MP and 
PP sessions than during the placebo session. The total intake of Na (diet + supplements) 
during the placebo session was 1.4 g, during the MP session 2.5 g, and during the PP 
session 3.2 g. The intakes of selected nutrients during the study sessions are presented in 
Table 6. We hypothesized that the PP supplement would decrease Ca absorption, and 
consequently, increase the S-PTH concentration more than would the MP supplement. 
 
Table 6.  Intakes of selected nutrients from the diet during the study sessions (Study IV). 
Variable Intake 
Energy (MJ) 8.1 
Calcium (mg) 340 
Phosphorus (mg) 500 
Sodium (mg) 1370* 
Fibre (g) 20 
* During the phosphate supplement sessions sodium intake was higher since the phosphate supplements 
contained sodium. 
4.2.2.3 Sampling 
The timing of the blood samples is shown in Figure 5 (Study III) and Figure 6 (Study IV). 
The blood samples were taken before meals at all other times except at 18:00 hours, when, 
for practical reasons, it was taken immediately after the meal. Venoject gel tubes were 
used to obtain clear sera. Blood samples were handled anaerobically and centrifuged (3000 
rpm for 15 min) within an hour of sampling. The 24-h urine collections were obtained on 
the study day from 08:00 to 08:00 hours the following morning. Both serum samples and 
portions of urine were stored at -20ºC until analysed. 
4.2.3 Laboratory analyses 
The serum ionized calcium (S-iCa) concentration was analysed from anaerobically 
handled serum samples with an ion selective analyser (Microlyte 6; Thermo Electron Oy, 
Vantaa, Finland) within 90 min of sample collection. In the other measurements, all 
samples from the same person were analysed in the same assay in randomized order. In 
Study III, intact S-PTH concentration was measured by an immunoenzymometric assay 
using Octeia® Intact PTH Kits (Immunodiagnostic Systems, Boldon, UK). In Study IV, 
the serum intact PTH concentration was measured by radioimmunoanalysis using Allegro 
intact PTH Assay Kits (Nichols Institute, San Juan Capistrano, CA, USA). Serum bone-
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specific alkaline phosphatase (BALP) activity was determined only in Study III by an 
enzyme immunoassay (Metra™ BAP EIA Kit; Quidel, San Diego, CA, USA). Similarly, 
excretion of urinary N-terminal telopeptide of type I collagen (NTx) was analysed only in 
Study III by an enzyme-linked immunosorbent assay using Osteomark® NTx Test Kits 
(Ostex International, Seattle, WA, USA). Serum Pi and creatinine concentrations and 
excretions of urinary Ca, Pi, and creatinine were measured with an autoanalyser (Konelab 
20, Thermo Electron, Vantaa, Finland).  
 
All analyses were conducted at the laboratory of the Department of Food and 
Environmental Sciences, Division of Nutrition, University of Helsinki. Laboratory 
methods and intra- and inter CV% of methods are presented in Table 7. 
 
Table 7. Laboratory measurements and intra- and inter CV% of methods in Studies III and 
IV. 
Variable Method CV% intra CV% inter 
Serum measurements  Study 
III 
Study 
IV 
Study 
III 
Study 
IV 
Serum ionized calcium (S-iCa) Ion selective 
analyser 
1.7 1.6 - - 
Serum intact parathyroid 
hormone (S-PTH) 
IEMA (Study III) 
IRMA (Study IV) 
1.0 2.9 4.2 5.1 
Serum bone-specific alkaline 
phosphatase (S-BALP) 
ELISA 5.4 - 7.4 - 
Serum phosphate (S-Pi) Spectrophotometric 1.1 1.4 1.4 3.3 
Serum creatinine (S-Crea) Spectrophotometric 2.4 - 1.1 - 
Urinary measurements      
Urinary calcium (U-Ca) Spectrophotometric 1.1 2.1 1.4 4.3 
Urinary phosphate (U-Pi) Spectrophotometric 1.7 2.8 3.5 3.5 
Urinary creatinine (U-Crea) Spectrophotometric 1.7 3.0 3.6 3.5 
Urinary N-terminal telopeptide 
of type I collagen (U-NTx) 
ELISA 4.6 - 6.4 - 
ELISA= enzyme-linked immunoassay; IEMA=immunoenzymometric assay; IRMA=immunoradiometric 
assay; - not analysed  
4.3.3 Statistical methods 
The data are expressed as mean ± SEM (standard error of the mean). For serum variables, 
the area under the curve (AUC) for the difference from the morning fasting value was 
calculated. To exclude the effect of the first fasting sample, the deltas of the 0-h sample to 
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the 24-h sample were used in the analyses. In Study III, the morning fasting values of 
serum phosphate, iCa, PTH, and BALP from the second-day (24 h from the first blood 
sample) fasting samples were compared in addition to AUC values. Non-normal 
distributions were normalized by logarithmic transformations. 
 
Analysis of variance (ANOVA) with repeated measures was used to compare the study 
sessions. If the sphericity assumption was violated, a Huynh–Feldt adjustment was 
applied. Contrast analysis was used for pairwise comparisons between study sessions. In 
Study III, analyses were conducted with the SPSS 10.0 statistical package (SPSS Inc., 
Chicago, IL, USA), and in Study IV with PASW Statistics 17.0.2 (SPSS Inc., Chicago, IL, 
USA). Both versions of SPSS software were used in a Windows environment for all 
statistical analyses. We regarded p<0.10 as a trend and p>0.05 as a statistically significant 
difference. 
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5 Results 
5.1 Total and in vitro digestible phosphorus content of foods 
(Studies I and II) 
5.1.1 Meat and meat products 
In sausages and cold cuts, the TP contents varied between 175 and 279 mg/100 g. The 
highest values were found in boiled ham containing phosphate additives. The TP content 
of a salami-type sausage was similar to that of a low-fat processed sausage, but the DP 
content of the former was 24% lower than that of the latter. The sodium content of the 
salami-type sausage (1.7 g/100 g) was the highest among foods analysed in this study. The 
P contents in frankfurters were slightly lower than those in other sausages or cold cuts. 
The TP contents varied between 199 and 232 mg/100 g in raw meats and rainbow trout. 
More variation seemed to exist in the DP contents of the meats (147 to 207 mg/100 g). The 
results of meat and meat products are shown in Table 8. 
Table 8.  Total and in vitro digestible P, protein, P-to-protein ratios, sodium contents, and 
P additives of meats and meat products. 
aProtein and sodium contents based on Fineli®.  
bProtein and sodium contents based on food labels.  
cP additives listed in Table 1 in Appendix II.  
Product TP /100g DP/100g Protein/ 
100g 
TP-to-
Protein 
Ratio 
(mg/g) 
DP-to-
Protein 
Ratio 
(mg/g) 
Na 
(g/100g) 
P 
additivesc 
Processed sausage, 18% fat  210 224 9b 23.3 24.9 0.9b E450, 
E451 
Processed sausage, light,     
10% fat 
241 242 10b 24.1 24.2 0.8b E450 
Frankfurter pool, 20% fat 175 144 9.2b 19.0 15.7 0.8b E450, 
E451 
Frankfurter pool, light,  
13% fat 
186 130 10b 18.6 13.0 0.7b E450 
Sausage, dry, salami type 244 171 21.5b 11.4 7.9 1.7b E450 
Sausage cold cuts 184 164 10.7b 17.2 15.4 0.8b E450, 
E451 
Boiled ham 279 255 17.9b 15.6 14.3 0.75b E450, 
E451, 
E452 
Raw pork steak 212 161 21a 10.1 7.7 0.06a - 
Raw chicken fillet 229 191 23a 10.0 8.3 0.08a - 
Raw beef 199 147 22a 9.1 6.7 0.04a - 
Raw rainbow trout fillet 232 207 16.8a 13.8 12.3 0.05a - 
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TP = total phosphorus; DP = in vitro digestible phosphorus 
5.1.2 Dairy products 
The highest TP and DP contents were observed in cheeses. The TP contents of processed 
cheeses varied between 574 and 892 mg/100g, 89-100% of which was DP. Sodium 
contents of processed cheeses were about twice (1.0-1.2g/100g) the amount found in 
unprocessed hard cheeses. In unprocessed hard cheeses, the TP contents were 529-638 
mg/100g, but the DP contents were lower (53-76% of TP). TP, DP, and sodium contents of 
cottage cheese were substantially lower than in processed or hard cheeses. Compared with 
milk, the TP content of cottage cheese was slightly higher, but the DP content was even 
lower. The results of dairy products are shown in Table 9. 
 
Table 9. Total and in vitro digestible P, protein, P-to-protein ratios, sodium contents, and P 
additives of the foods analysed. 
*Protein and sodium contents based on Fineli®.  
TP= total phosphorus; DP=in vitro digestible phosphorus 
Product TP/100g DP/100g Protein/10
0g 
TP-to-
Protein 
Ratio 
(mg/g) 
DP-to-
Protein 
Ratio 
(mg/g) 
Na 
(g/100g) 
P 
additives 
Milk, 1.5% fat 108 85 3.2 33.8 26.6 0.04* - 
Skimmed milk 122 75 3.3 36.9 22.7 0.04* - 
Processed cheese, individually 
packed slices, 5% fat 
574 589 23 24.9 25.6 1.1 E339, 
E452 
Processed cheese, individually 
packed slices, 12% fat 
647 720 24 27.0 30.0 1.2 E452, 
E339 
Processed cheese, individually 
packed slices, 23% fat  
584 576 21 27.8 27.4 1.1 E452, 
E339 
Cheese spread, 9% fat 92 794 18 49.6 44.1 1 E452, 
E339 
Cheese spread, 22% fat 755 772 19 39.7 40.6 1.1 E452, 
E339 
Hard cheeses pool,  
5-17% fat 
638 484 30.3 21.1 16.0 0.54 - 
Hard cheeses pool,              
24-29% fat 
529 282 26.5 20.0 10.6 0.56 - 
Cottage cheese 146 71 13.8 10.6 5.1 0.3 - 
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Figure 7 Proportions of in vitro digestible P to total P among meat and dairy products. 
5.1.3 Plant foods 
Of the breads analysed, the highest P content was found in rye crisp (TP 291 mg/100 g and 
DP 191 mg/100 g) due to its low water but high whole-grain content. Apart from the 
pooled crisp bread, the TP content of all other breads was similar. More variation relative 
to TP results was found in DP contents of breads. DP content of two very similar small rye 
breads containing potato differed, being 89 and 54 mg/100 g. High content of both TP 
(212 mg/100 g) and DP (201 mg/100 g) was also found in industrial muffins, which 
contain phosphate additives.   
 
Practically all P in cola drinks and beer was soluble (10-16 mg/100 g in cola drinks; 22 
mg/100 g in beer), but both DP and TP contents/100 g of the food were the lowest among 
the analysed foods. In legumes, seeds, and products prepared from legumes, TP content 
varied between 59 mg/100 g of soaked chickpea and 667 mg/100 g of sesame seed. 
Legumes contained an average DP content of 83 mg/100 g (38% of TP). The TP and DP 
contents and TP- and DP-to-protein ratios of plant foods analysed are presented in Table 
10. Phytic acid contents of some of the analysed foods based on previously published data 
are also shown in the table. Proportions of DP to TP are shown in Figure 8.  
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Table 10. Total and in vitro digestible P, protein, and phytic acid contents, and P-to-protein 
ratios of the analysed plant foods.  
a Contains sodium polyphosphate as an additive 
b Contains phosphoric acid as an additive 
c Value provided by manufacturer  
d Value based on National Institute for Health and Welfare (2011) 
e Value based on Food Standards Agency (2002) 
f Value based on Plaami & Kumpulainen (1995) 
g Value based on Holland et al. (1988) 
h Value based on Holland et al. (1992) 
I Value based on Holland et al. (1991) 
 
Product TP/100
g 
DP/100g Protein/100
g 
TP-to-protein 
ratio (mg/g) 
DP-to-protein 
ratio (mg/g) 
Phytic acid g/100g 
Rye bread pool 208 123 8.2c 25.4 15 0.3f 
Rye crisp 291 191 10.1c 28.8 18.9 3.2/0.8/4.4f 
Small rye bread 
containing potato 1 
192 89 8.2c 23.5 10.9 Not available 
Small rye bread 
containing potato 2 
206 54 10c 20.6 5.4 Not available 
Mixed grain bread with 
seeds 
189 116 9.7c 19.5 12.0 Not available 
Muffin poola 212 201 6.6d 32.1 30.5 0.11g 
Sweet bun pool 116 60 7.7c 15.1 7.8 0.8f 
Cookie pool 125 43 6.1c 20.5 7.0 0.03-0.37g 
Sesame seed (with hull) 667 42 26.9d 24.8 1.6 1.38h 
Tofu (firm) 164 51 16.5c 9.9  3.1 0.84i (steamed, 
fried) 
Green bean 57 24 1.9d 30.2 12.4 0.01i 
Green pea (frozen)  118 50 5.1d 23.1 9.7 0.02i 
Chickpea (soaked) 149 53 8.4d 17.7 6.3 0.5i(raw, unsoaked) 
Red lentil 432 167 23.8e 18.2 7.0 0.26i 
Green lentil 400 120 24.4d 16.4 4.9 0.49i 
Pepsi Maxb 14 15 <0.1 gc Not applicable Not applicable Not available 
Coca-Cola lightb 13 13 0c Not applicable Not applicable Not available 
Coca-Colab 19 16 0c Not applicable Not applicable Not available 
Cola poolb 17 16 <0.1 gd Not applicable Not applicable Not available 
Freeway Cola lightb  11 10 <0.1 gd Not applicable Not applicable Not available 
Beer 21 22 0.4d 52.5 55 Not available 
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Figure 8 Proportions of in vitro digestible P to total P among plant foods. 
5.1.4 Summary of results (Studies I and II)  
When considering the highest and lowest P contents of all analysed foods, differences 
exist among TP and DP results. Tables 11 and 12 show the foods with the highest and the 
lowest TP and DP contents. Interestingly, all of the foods containing the highest absolute 
amounts of DP contained P additives.  
 
Table 11. Foods containing the highest amounts of TP and DP (Studies I and II).    
Food group TP content 
(mg/100 g) 
Food group DP content 
(mg/100 g) 
Processed and hard cheeses  529-892 Processed and hard cheeses 282-794 
Sesame seeds 667 Boiled ham 255 
Lentils 400-432 Processed sausages 224-242 
Rye crisp 291 Muffin pool 201  
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Table 12. Foods containing the lowest amounts of TP and DP (Studies I and II).  
Food group TP content (mg/100 g) Food group DP content (mg/100 g) 
Colas and beer 11-21 Colas and beer 10-22 
Green bean 57 Green bean 24 
Milk 108-122 Sesame seed 42 
Sweet bun pool 116 Cookie pool 43 
Green pea 118 Green pea* 50 
          *Several other plant foods with DP content 51-60 mg/100 g. 
 
Tables 13 and 14 show the foods with the highest and the lowest TP- and DP-to-protein 
ratios. Among plant foods, all analysed foods, except beer, muffins, and rye crisp, had DP-
to-protein ratios <15. Of foods of animal origin, only cottage cheese was among the foods 
with the lowest DP-to-protein ratios. 
 
Table 13. Foods containing the highest TP- and DP-to-protein ratios (Studies I and II).  
Food group TP-to-
protein ratio 
Food group DP-to-protein 
ratio 
Beer 52.5 Beer 55 
Cheese spread, 9% fat 49.6 Cheese spread, 9% fat 44.1 
Cheese spread, 22% fat 39.7 Cheese spread, 22% fat 40.6 
Muffin pool 32.1 Muffin pool 30.5 
Green bean 30.2 Processed cheese, individually 
packed slices, 12% fat 
30.0 
  
Table 14. Foods containing the lowest TP- and DP-to-protein ratios (Studies I and II).  
Food group TP-to-protein ratio Food group DP-to-protein ratio 
Raw beef 9.1 Sesame seed 1.6 
Tofu (firm) 9.9 Tofu (firm) 3.1 
Raw chicken fillet 10.0 Green lentil 4,9 
Raw pork steak 10.1 Cottage cheese 5.1 
Cottage cheese 10.6 Small rye bread 
containing potato 2 
5.4 
 
  
 
63
5.2 Human studies (Studies III and IV) 
5.2.1 Habitual dietary intakes 
Basic characteristics of the subjects and their mean habitual intakes of selected nutrients 
are shown in Table 15. The mean habitual P intake exceeded nearly 2.5-fold the 
recommendation for P in this age group (600 mg/d) (National Nutrition Council 2005). On 
average, Ca intake was also ample.  
 
Table 15. Background characteristics and mean habitual dietary intakes of subjects (SD)               
in Studies III and IV.  
Variable Study III (n=16) Study IV (n=12) 
Age (years, range) 20-30 19-31 
Body mass index (kg/m2) 21.8 (2.2) 21.7 (1.6) 
Energy intake (MJ/d) 7.5 (1.3) 7.3 (1.2) 
Protein intake (g/d) 75 (24) 77 (26) 
Phosphorus intake (mg/d) 1440 (406) 1580 (415) 
Calcium intake (mg/d) 1030 (316) 1040 (320) 
5.2.2 Serum phosphate and urinary phosphate excretion 
In Study III, the S-Pi concentrations (AUC) differed between the study sessions (p= 
0.0001, ANOVA) (Figure 9). The S-Pi concentration was elevated during the meat 
(p=0.0001), cheese (p=0.0001), whole-grain (p=0.006), and supplement (p=0.0001) 
sessions compared with the control session. Cheese increased the S-Pi concentration more 
than the other Pi sources (p=0.0001). Differences were present between study sessions in 
the S-Pi concentrations in the second-day fasting samples (p=0.0001, ANOVA). The S-Pi 
concentration remained higher in the cheese session on the following morning than in all 
other sessions (p=0.032-0.0001). Differences were found in U-Pi excretion between study 
sessions (p=0.0001, ANOVA) (Figure 9). U-Pi was higher in all Pi sessions than in the 
control session (p=0.001-0.0001). Meat increased U-Pi excretion more than grain 
(p=0.003) or cheese (p=0.005). The Pi supplement also increased U-Pi more than grain 
(p=0.001) or cheese (p=0.027).  
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Figure 9 Study III. Changes in serum phosphate (S-P) concentration (A) and 24-h urinary 
excretion of phosphate (U-P) (B) during the five study sessions. A: control (□), meat 
(●), supplement (▼), cheese (*), grain (♦. Arrows indicate mealtimes. The different 
phosphorus sources affected the AUC values of S-P ( p=0.0001, ANOVA) and 24-h U-
P ( p=0.0001, ANOVA); asignificantly different from control session, bsignificantly 
different from grain and cheese sessions, csignificantly different from all other 
sessions. 
In Study IV, the S-Pi concentrations differed among the study sessions (p=0.0001, 
ANOVA) (Figure 10). The results of U-Pi were corrected for U-Crea excretion before the 
statistical analyses. Both MP (p=0.0001) and PP (p=0.0001) increased S-Pi compared with 
the control session. The difference between the MP and PP sessions in S-Pi was not 
statistically significant (p=0.18). Differences were found in the U-Pi excretion among the 
study sessions (p=0.0001, ANOVA) (Figure 10). Both MP and PP increased U-Pi 
compared with the control session (p=0.0001, both). No differences between the MP and 
PP sessions in U-Pi excretion were found (p=0.33). 
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Figure 10 Study IV. Changes in serum phosphate (S-Pi) concentration (A) and 24-h urinary 
excretion of phosphate (U-Pi/Crea) (B) during the three study sessions. A: control 
(□), monophosphate (●), polyphosphate (▲). The supplement administration times 
are indicated with an arrow. The supplements affected the area under the curve 
values of S-Pi ( p=0.0001, ANOVA) and 24-h U-Pi/Crea (p=0.0001, ANOVA); 
asignificantly different from control session. 
5.2.3 Serum ionized calcium and urinary calcium excretion  
In Study III, the different foods affected the AUC of serum ionized calcium (S-iCa) 
(p=0.0001, ANOVA) and urinary calcium excretions (U-Ca) (p=0.0001, ANOVA) (Figure 
11). The S-iCa concentration was greater in the cheese session due to high Ca intake than 
in the other sessions (p=0.0001). During the Pi supplement session, S-iCa concentration 
was lower than in the control session (p=0.027). Whole-grains (p=0.682) and meat 
(p=0.282) had no effect on S-iCa concentration relative to the control session. On the 
following morning, S-iCa concentration differed between study sessions (p=0.039, 
ANOVA). The 24-h morning fasting value was higher in the cheese session than in the 
supplement (p=0.018), whole-grain (p=0.023), or control (p=0.025) sessions and tended to 
be higher in the cheese session than in the meat session (p=0.050), but did not reach 
statistical significance. The U-Ca was higher during the cheese session than during all 
other sessions (p=0.0001) (Figure 11). In the meat session, the U-Ca was greater than in 
the Pi supplement session (p=0.003). 
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Figure 11 Study III. Changes in serum ionized calcium (S-iCa) concentration (A) and 24-h 
urinary excretion of calcium (U-Ca) (B) during the five study sessions. A: control (□), 
meat (●), supplement (▼), cheese (*), grain (♦). Arrows indicate mealtimes. The 
different phosphorus sources affected the AUC values of S-iCa (p=0.0001, ANOVA) 
and 24-h U-Ca (p=0.0001, ANOVA); asignificantly different from control session, 
csignificantly different from all other sessions, dsignificantly different from phosphate 
supplement session. 
In Study IV, the S-iCa concentrations did not differ among study sessions (p=0.29, 
ANOVA) (Figure 12). The results of U-Ca were corrected for U-Crea excretion before the 
statistical analyses. The U-Ca excretion differed between the study sessions (p=0.001, 
ANOVA) (Figure 12). Only PP decreased the U-Ca in a statistically significant manner 
(p=0.002). However, the U-Ca excretion tended to decrease in the MP session relative to 
the control session (p=0.069). The PP decreased the U-Ca more than did the MP 
(p=0.014). 
  
 
67
 
 
 
Figure 12 Study IV. Changes in serum ionized calcium (S-iCa) concentration (A) and 24-h 
urinary excretion of calcium (U-Ca/Crea) (B) during the three study sessions. A: 
control (□), monophosphate (●), polyphosphate (▲). The supplement administration 
times are indicated with an arrow. The supplements did not affect the area under the 
curve values of S-iCa (p=0.29, ANOVA), but affected the 24-h U-Ca/Crea (p=0.001, 
ANOVA); asignificantly different from control session. 
5.2.4 Serum parathyroid hormone concentration 
In Study III, the AUC values of S-PTH differed between the study sessions (p=0.0001, 
ANOVA) (Figure 13). Compared with the other sessions, cheese decreased S-PTH most 
(p=0.0001). Pi supplement, by contrast, increased S-PTH concentration compared with the 
control session (p=0.039). Meat (p=0.346) or grain (p=0.498) had no effect on S-PTH. 
Differences were observed between study sessions in S-PTH concentrations of the second-
day fasting samples (p=0.018, ANOVA). The S-PTH concentration was lower in the 
cheese session on the following morning than in all other sessions (p=0.048-0.004). 
 
  
 
68
0 2 4 6 8 10 12
0
1
2
3
4
a)
c)
24
Time (h)
S-
PT
H
 (p
m
ol
/L
)
 
Figure 13 Study III. Changes in serum parathyroid hormone (PTH) concentration  during 
control (□), meat (●), supplement (▼), cheese (*), and grain (♦) sessions. Arrows 
indicate mealtimes. The different phosphorus sources affected the AUC values of S-
PTH (p=0.0001, ANOVA); asignificantly different from control session, csignificantly 
different from all other sessions. 
In Study IV, the S-PTH concentrations differed between the study sessions (p=0.019, 
ANOVA) (Figure 14). Both MP (p=0.048) and PP (p=0.012) increased the S-PTH 
compared with the control session. The increase in S-PTH was equal with both Pi salts 
(p=0.74). 
 
 
 
 
Figure 14 Study IV. Changes in serum parathyroid hormone (S-PTH) concentration during the 
three study sessions. Control (□), monophosphate (●), polyphosphate (▲). The 
supplement administration times are indicated with an arrow. The supplements 
affected the AUC values of S-PTH (p=0.019, ANOVA); asignificantly different from 
control session. 
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5.2.5 Markers of bone metabolism (Study III) 
Based on ANOVA, the AUC values of the activity of serum BALP (S-BALP) tended to 
differ among study sessions (p=0.094) (Figure 15), but did not reach statistical 
significance. In contrast analysis, the activity of S-BALP was higher in the meat session 
than in the control (p=0.045) or whole-grain (p=0.013) session. The second-day fasting 
values of S-BALP were not different among sessions (p=0.403, ANOVA).  
 
Differences were present in urinary NTx excretions (U-NTx) among study sessions 
(p=0.0001, ANOVA) (Figure 15). The U-NTx was higher in the meat session (p=0.049) 
than in the control session. U-NTx excretion tended to increase in the whole-grain (p= 
0.053) and Pi supplement (p=0.083) sessions compared with the control session, but did 
not reach statistical significance. The NTx excretion was lower during the cheese session 
than during the control session (p=0.008). The NTx results are shown as bone collagen 
equivalents (nmol BCE) without creatinine corrections due to the differences in U-Crea 
results among the study sessions.  
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Figure 15 Study III. Changes in serum BALP (S-BALP) activity from the morning fasting value 
(A) and 24-hour urinary excretion of NTx (U-NTx) (B) during the five study sessions. 
A: control (□), meat (●), supplement (▼), cheese (*), grain (♦). Arrows indicate 
mealtimes. The different phosphorus sources tended to affect the AUC values of S-
BALP (p=0.094, ANOVA) and affected U-NTx (p=0.0001, ANOVA); asignificantly 
different from control session. 
5.2.6 Serum creatinine and urinary creatinine excretion (Study III) 
In Study III, the AUC values of serum creatinine (S-Crea) concentrations (p=0.0001, 
ANOVA) and urinary excretion of creatinine (U-Crea) differed among study sessions 
(p=0.0001, ANOVA) (Figure 16). Because meat has a high creatinine content, the S-Crea 
concentration was higher in the meat session than any of the other sessions (p=0.0001). 
The S-Crea concentration was higher in the cheese session than in the control session 
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(p=0.038). The U-Crea was greater in the meat session than in all other sessions (p=0.021-
0.0001) (Figure 16). Also, in the cheese session, the U-Crea was higher than in the control 
(p=0.030) or whole-grain (p=0.019) sessions. Due to the differences in U-Crea, the results 
of U-Pi, U-Ca, and U-NTx were not corrected for U-Crea, as this would have skewed the 
results. In Study IV, no differences were found in S-Crea and U-Crea (data not shown). 
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Figure 16 Study III. Changes in serum creatinine (S-Crea) concentration (A) and 24-h urinary 
excretion of creatinine (U-Crea) (B) during the five study sessions. A: control (□), 
meat (●), supplement (▼), cheese (*),grain (♦). Arrows indicate mealtimes. The 
different phosphorus sources affected the AUC values of S-Crea (p=0.0001, ANOVA) 
and 24-h U-Crea (p=0.0001, ANOVA); asignificantly different from control session, 
csignificantly different from all other sessions. 
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6 Discussion 
6.1 Phosphorus content of foods 
6.1.1 Meat and meat products 
Of the foods analysed, raw meats and meat products were not among those with the 
highest TP contents, but the DP contents of some processed meats were among the highest 
(Table 11). When raw meats were compared, only small differences were found among 
chicken, pork, beef, and rainbow trout. Our TP results of these P additive–free meats are 
similar to those of unenhanced meats published previously (Sullivan et al. 2007, Sherman 
& Mehta 2009b). Compared with those of sausages and cold cuts, the P-to-protein ratios 
and sodium contents of the unenhanced meats are lower, hence more beneficial to CKD 
patients. The DP contents of raw meats varied more than the TP contents, the lowest DP 
content being found in beef and the highest in rainbow trout. However, TP and DP 
contents of cooked meats should be analysed, as cooking itself and likely also the cooking 
method affect the P content of a food (Cupisti et al. 2006, Delgado-Andrade et al. 2011). 
 
In sausages and cold cuts, the lowest percentages of DP to TP were found in the salami-
type sausage and in low-fat frankfurters. The content of P additives in the salami-type 
sausage was likely lower than that in other sausages, as one of the sausages in the salami-
type sausage pool did not contain any P additives. Also, the consistency of salami is 
different from that of other sausages. Phosphates increase the water content of a product, 
which is an unwanted quality in a salami-type sausage. Due to its high protein content, the 
P-to-protein ratios of the salami-type sausage were surprisingly low; by contrast, the 
sodium content of the salami-type sausage was the highest among the foods of this study. 
Our results indicate that frankfurters may contain less P than other sausages, but other 
brands should be analysed before drawing further conclusions. Also, sausages prepared 
without P additives should be analysed for comparisons with current products. As the 
market shares of P additive–free sausages are small (at least in Finland), these products 
were not analysed here.  
6.1.2 Dairy products 
All processed and hard cheeses had the highest TP and DP contents among all foods 
analyzed. Our results confirm previous data on cheeses as P-rich foods, as an extremely 
high content of DP was found in processed cheeses. In Study III, fermented cheese (not 
containing P additives) increased the S-Pi concentration more than meat, whole-grains, or 
even a mixture of P additives, suggesting that P from cheese is easily absorbed. 
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Furthermore, in a cross-sectional study on a randomly selected subgroup of 31- to 43-year-
old Finnish women, consumption of processed cheeses was associated with a higher mean 
S-PTH concentration (Kemi et al. 2009). 
 
Variation in both DP (589 to 794 mg/100 g) and TP (574 to 892 mg/100 g) can be found 
among processed cheeses. The P contents seem not to depend on the fat or protein content 
of the processed cheese. However, in cheese spreads, the TP and DP contents seem to be 
higher than in sliced processed cheese. Possibly, the softer texture of cheese spreads 
requires more P additives than the harder texture of sliced, processed cheeses. The sodium 
contents in processed cheeses are substantially higher than those in other types of cheeses; 
part of the sodium is from the sodium phosphate additives. It is notable that the use of 
sodium phosphate-containing processed cheeses may substantially increase not only P 
intake but also sodium intake. Furthermore, the P-to-protein ratios of processed cheeses 
are extremely high (Table 13), thus further confirming that they are unsuitable in the diet 
of CKD patients. 
 
Contrary to other cheeses, cottage cheese had the lowest absolute DP content and DP-to-
TP proportion among the milk and meat products, and one of the lowest TP- and DP-to 
protein ratios among all foods analysed. The P contents of fresh cheeses are lower than 
those of hard cheeses or processed cheeses because of the higher water content and 
different preparation technique of fresh cheeses. When considering the diets of CKD 
patients, due to the low P-to-protein ratio and sodium content, cottage cheese is clearly 
more beneficial than hard or processed cheeses.  
6.1.3 Plant foods 
Of the foods analysed in this study, the proportion of DP was lowest in legumes and seeds 
(6-42% of TP). Sesame seed was among the foods with the highest TP content, but also 
among the foods with the lowest DP content, which could mean that at least some seeds 
are poor P sources. If confirmed in further analyses, this result would indicate that whole 
sesame seeds, possibly some other seeds as well, could be used in a P-restricted diet. In a 
short-term controlled study, sesame seeds did not increase S-Pi relative to the control 
session (Kärkkäinen et al. 1997), which is in line with the present results.  
 
Earlier, it has been suggested that only 25% of P from beans actually gets absorbed 
(Uribarri 2007). Even though our results of DP in legumes are on average higher than this, 
they support the opinion presented recently (Kalantar-Zadeh et al. 2010) on the use of 
legumes in patients with CKD: very strict limitations appear to be unnecessary. Further, 
our results are in line with those of a crossover trial comparing the effects of vegetarian 
and meat protein sources on P homeostasis in CKD (Moe et al. 2011). The cooking time of 
lentils, green beans, and peas is relatively short, and these legumes do not require soaking 
before cooking. A large amount of phytic acid is therefore unlikely to be hydrolysed when 
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cooking these legumes. Thus, the DP content in lentils, green beans, and peas is 
anticipated to not increase notably when these products are cooked. However, further 
analyses on cooked legumes are required to evaluate P absorption, especially for those 
requiring a longer cooking period such as chickpeas and several beans. Analyses on phytic 
acid content of differently processed legumes, seeds, and grain products could also 
improve knowledge of P availability.  
 
In cola drinks and beer, all P was digestible. This result is in accordance with past 
information on absorbability of P from food additives because all P in cola drinks is from 
phosphoric acid, which is likely to degrade efficiently in the intestine. TP content in cola 
drinks was similar to the values published earlier (Murphy-Gutekunst 2005). In beer, P is 
from the grain used in preparing beer; in Finland, this is most often barley. On the basis of 
these results, it seems that during malting and other processing of grain when preparing 
beer, P is efficiently released from the grain in a highly digestible form, resulting in even 
higher P content than in cola beverages. 
 
DP content of different rye breads may vary substantially, likely depending on the amount 
and proportion of rye flour and crushed rye grain, the content of other grains, the use of 
yeast, and the length of fermentation. White bread, the P content of which is known to be 
lower than that of whole-grain breads, was not analysed. According to our previous 
analyses using the same method, we found that DP content of white bread is also lower 
than that of rye or mixed-grain bread. However, based on these results, a rye bread with a 
lower P bioavailability than in the currently available rye breads could potentially be 
developed. The possibility of using rye bread to some extent in a P-restricted diet would 
likely improve compliance with the diet in countries where rye bread is a staple food. 
Furthermore, whole-grain consumption is associated with a lower risk of cardiovascular 
diseases and mortality (Jacobs et al. 2000, Liu et al. 2000). 
 
When considering sweet bakery products, buns (leavened with yeast) and cookies (P 
additive-free) have a P content similar to that in white bread. A striking difference to other 
wheat products was, however, found in industrially prepared muffins containing a P 
additive (baking powder). TP content of muffins was similar to that of rye bread, but DP 
content was higher than in any breads. Therefore, individuals consuming large amounts of 
bakery products with a P-containing baking powder may have an elevated intake of highly 
bioavailable P, suggesting that bakery products can be another important source of DP in 
addition to meat products, processed cheeses, and carbonated beverages. 
6.1.4 Conclusions about the phosphorus content of foods 
Both TP and DP contents varied widely between the different food groups analysed and 
also within many food groups. Results of TP can largely be explained by protein content 
of the food and/or use of P-containing food additives. Proportion of DP to TP content 
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seems to be affected by processing of the food in phytic acid-containing plant foods and by 
the presence of P-containing food additives. Furthermore, our results support previous 
findings of better P absorbability in foods of animal origin. Variation among similar 
products does, however, exist. This variation often depends not only on the protein or fat 
content of the food but also on the use of P additives, which is affected by the desired 
texture of the food. 
 
In conclusion, the most beneficial P sources for CKD patients and for any other persons 
wishing to reduce their P intake could be legumes (and products prepared from them, e.g. 
tofu), fresh cheeses, and whole seeds. Of foods of animal origin,‘‘natural’’ unenhanced 
meats are a better choice in terms of P-to-protein ratios and sodium contents than 
processed or hard cheeses, sausages, and cold cuts. More research is, however, needed on 
the P contents of different foods and the absorbability of P from different foods with an in 
vivo method.     
6.2 Dietary interventions 
6.2.1 Effects of P sources on serum and urinary phosphate concentration as 
indicators of bioavailability       
Serum and urinary Pi concentrations are indirect measures of absorbed P, and U-Pi is 
affected by PTH secretion. Still, in a controlled setting, comparing S- and U-Pi during 
different sessions provides information on P absorbability. Based on S-Pi and U-Pi in 
Study III, P from meat and supplements appears to absorb better than P from whole-grains. 
The whole-grain foods given to the subjects (oatmeal porridge, rye bread) were 
unfermented. Because fermentation can enhance the absorption of minerals in phytate-
containing foods, the bioavailability of P may be greater from fermented whole-grains and 
even greater from low-fibre grains. However, in Studies I and II the DP content seemed to 
be higher in cheese and meat than in grains and legumes. The P supplements and meat had 
similar effects on S-Pi and U-Pi. As meat did not affect S-PTH, more research is needed to 
clarify whether this difference is due to variation in absorbability, protein intake, or 
another factor. 
 
Estimation of the absorbability of P from cheese is more complex than that of whole-
grains because the high Ca content decreases PTH secretion, which in turn decreases U-Pi. 
Hence, the low U-Pi excretion in the cheese session was probably due to low S-PTH 
concentration caused by high Ca intake. S-Pi increased during the cheese session more 
than during any other session. Decreased U-Pi caused by low PTH secretion may have 
caused an increase in S-Pi by elevating the renal P threshold. At the same time, a decrease 
in bone resorption (as indicated by lowered NTx excretion) likely caused a drop in the 
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release of P from bone, which could decrease S-Pi concentration. The effects of these two 
mechanisms on S-Pi are, therefore, the opposite. P intake during the cheese session (1624 
mg) was slightly higher than during other P sessions, which may also have increased S-Pi 
concentration. In addition, the high Ca intake (290-602 mg/meal) may have partly 
inhibited the absorption of P in the intestine. Based on this study, we do not know whether 
this inhibition occurred. Probably many of these factors simultaneously affected S-Pi in 
the cheese session, the outcome being increased S-Pi. However, based on another short-
term controlled study, both milk and cheese increase S-Pi efficiently, suggesting that P 
from dairy foods is well absorbed (Kärkkäinen et al. 1997).  
 
In Study IV, both Pi salts, commonly used in the food industry, affected S-Pi and U-Pi in a 
similar manner, and therefore, were likely to be absorbed equally well.  
6.2.2 Serum ionized calcium and urinary calcium excretion  
In Study III, the increase in S-iCa and U-Ca during the cheese session was expected due to 
the high Ca intake. Only the P supplement decreased S-iCa, which is in line with the 
increase in S-PTH during the P supplement session. Interestingly, meat did not affect S-
iCa despite similar increases in S-Pi and U-Pi. 
 
U-Ca excretion during the meat session was higher than during the P supplement session, 
but did not differ from the control session. Earlier, in a 10- to 15-day study, addition of 
meat to a diet low in protein, Ca, and P was observed to increase U-Ca (Schuette & 
Linkswiler 1982). The rise in U-Ca in response to increased dietary protein seems to be 
mostly due to enhanced intestinal Ca absorption (Kerstetter et al. 2005). It is possible that 
the increase in U-Ca in the P supplement session relative to the control session went 
unnoticed in our study, e.g. due to incomplete urine collections, or the magnitude of the 
increase was so small that we were unable to detect it. However, the difference in U-Ca 
during the meat and P supplement sessions is logical, as increased protein intake of the 
meat session is expected to increase U-Ca, and the increased S-PTH during the supplement 
session decreases U-Ca. 
 
In Study IV, the only significant difference between the MP and PP sessions was found in 
U-Ca, which PP decreased more than did MP. As a consequence of the increased level of 
S-PTH in both Pi sessions, a decrease in U-Ca in both sessions would have been expected. 
We consider it likely that MP ingestion also decreases U-Ca, even though in this study the 
decrease relative to the control session reached only the level of a trend.  
 
The larger decrease in U-Ca in the PP session than in the MP session was likely due to PP 
binding more Ca in the intestine than did MP (van Wazer & Callis 1958); hence, less Ca 
was absorbed in the PP session than in the MP session. To verify this conclusion, faecal 
collections would have been necessary. However, also in the study of Zemel and 
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Linkswiler (1981) in young men, the authors concluded that the greater Ca loss with the 
PP diet was due to a decrease in Ca absorption. In their study, no difference in U-Ca 
excretion between the MP and PP diets was observed, in contrast to our results. Based on 
differences in cAMP excretion (indicating differences in PTH secretion), the differences in 
U-Ca would have been expected since Ca intake was the same during both diets. In our 
study, two mechanisms may have contributed to the difference in U-Ca between the MP 
and PP sessions: reduced intestinal Ca absorption itself and possibly also increased PTH 
secretion, although we noted no statistical differences in S-PTH between the MP and PP 
sessions. In the study of Zemel and Linkswiler (1981), potassium (K) intakes differed 
between the MP and PP diets because the MP salt was a monobasic potassium phosphate 
and the PP salt was a sodium phosphate. The difference in K intake may explain the U-Ca 
results in their study since K increases the retention of Ca (Lemann et al. 1989). 
 
The MP and PP supplements did not affect S-iCa, even though in Study III and in previous 
similar intervention studies (Kärkkäinen & Lamberg-Allardt 1996, Kemi et al. 2006) 
similar amounts of P decreased S-iCa. Technical difficulties in performing the S-iCa 
probably affected the results. 
6.2.3 Parathyroid hormone 
Based on Studies III and IV, cheese decreases S-PTH due to its high Ca content, meat and 
grain have no effect on S-PTH, and P additives – both mono- and polyphosphates – 
increase S-PTH relative to the control session.  
 
The effect on mineral metabolism of P additives apparently differs from that of foods 
containing P naturally. In most interventions, P has been administered as a supplement 
(Portale et al. 1986, Calvo & Heath 1988, Silverberg et al. 1989, Brixen et al. 1992, 
Kärkkäinen & Lamberg-Allardt 1996, Kemi et al. 2006). In all of these studies, a rise in 
PTH secretion as a result of P administration was observed. At least two interventions 
have been conducted using diets assembled from common foods (Calvo et al. 1988, Calvo 
et al. 1990,). Also, in these studies a rise in S-PTH concentration with a low-Ca, high-P 
diet was found. However, the intake of P additives was probably rather high because the 
high-P test diet included several P additive-containing foods. For this reason, the effects of 
the high-P diets can be due to P additives in these studies, too. Moreover, Bell et al. (1977) 
observed enhanced parathyroid activity as a response to foods containing P additives 
compared with the same foods prepared without these additives. The PTH-rising effect of 
P additives compared with other sources could be due to their better absorbability.  
 
In Study IV, both Pi salts (MP and PP) increased S-PTH, which is in line with previous 
intervention studies conducted with P additives (Kärkkäinen & Lamberg-Allardt 1996, 
Kemi et al. 2006). Hence, both MP and PP affect PTH secretion similarly, even though 
previously MP increased U-cAMP (as a marker of PTH secretion) more than did PP 
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(Zemel & Linkswiler 1981). Since cAMP excretion is an indirect measure of PTH 
secretion, we consider our results more accurate. The rise in S-PTH may partly have been 
due to the Ca-binding capacity of Pi in the gut, especially PP. In the present study, 
however, we were unable to detect a difference in S-PTH between the MP and PP 
sessions. Possibly,t more samples would have been required to detect all of the differences 
in the serum measurements. As no samples were taken between 00:00–4:00 and 10:00–
24:00 hours, we do not know what happened with S-PTH, S-Pi, and S-Ca during these 
periods. With more frequent sampling, we also would have seen the diurnal variation of 
PTH and other serum measurements in more detail. 
 
Na intake may also increase PTH secretion by increasing Ca excretion (Evans et al. 1997).  
Na intake may increase U-Ca excretion, which could lead to a need to maintain S-Ca by 
increasing PTH secretion. Kärkkäinen & Lamberg-Allardt (1996) previously showed that a 
dose of 1.4 g Na as NaCl does not affect PTH secretion. In Study IV, the difference in Na 
intakes was highest (1.8 g) between the PP and control sessions, the differences between 
the control and MP sessions and the MP and PP sessions being 1.1 and 0.7 g, respectively. 
Theoretically, Na intake could have contributed to the S-PTH increase in the PP session. 
In that case, higher Ca excretion would have been expected. However, since Ca excretion 
was lowest in the PP session, we consider it unlikely that the difference in Na intakes 
would have explained the rise in S-PTH in the Pi sessions. 
6.2.4 Markers of bone metabolism (Study III) 
Urinary NTx excretion tended to increase in the P supplement session compared with the 
control session, implying greater bone resorption as a result of increased PTH secretion. 
Calvo et al. (1988) observed increased excretion of hydroxyproline, another marker of 
bone resorption, with a low-Ca, high-P test diet compared with the control diet (820 mg 
Ca, 930 mg P) in their 8-day study, but in their 4-week study, no difference in the 
excretion of hydroxyproline between the low-Ca, high-P test diet and control diet (800 mg 
Ca, 900 mg P) was found (Calvo et al. 1990). In two other studies, high P diets had no 
effect on the concentrations of resorption markers (Kärkkäinen & Lamberg-Allardt 1996). 
In the short-term study of Kemi et al. (2006), urinary excretion of NTx increased acutely 
as a response to 1500 mg of P administered as an inorganic P additive. Therefore, the 
results of NTx in the supplement session are in accordance with this previous study. 
Urinary NTx may respond to oral P load more rapidly than other resorption markers used 
in older studies. The differences in protocols of the P supplementation studies and 
sensitivities of different resorption markers probably explain the differences in results.  
 
Earlier, an acute decrease in serum BALP activity after administration of 1500 mg 
(Kärkkäinen & Lamberg-Allardt 1996, Kemi et al. 2006) and 750 mg (Kemi et al. 2006) 
of inorganic P was observed. In the present study, by contrast, the P supplement had no 
effect on serum BALP. This could be due to the timing and number of blood samples; 
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when the 14:00-hour blood sample (the first blood sample after the fasting sample) was 
taken, the subjects had only ingested ca. 500 mg of P from the supplement. The 18:00-
hour blood sample was taken immediately after the last P supplement dose. As the next 
blood sample was taken the following morning, we do not know whether serum BALP 
activity had decreased in the evening after 18:00 hours. 
 
During the meat session both bone formation and resorption increased, which may be due 
to the high protein intake from meat. The average protein intake in the meat session was 
2.1 g/kg body weight, which comprised 25% of total energy. Because protein consumption 
increases urinary Ca excretion, high protein intake has been speculated to be detrimental to 
bone health (Kerstetter et al. 2003). The effect of protein intake on bone seems, however, 
to depend on the protein source as well as on other nutrients in the food (Massey 2003).  
 
The increase in both BALP and NTx probably indicates increased turnover of bone during 
the meat session. The effects of meat proteins and meat phosphates on bone should be 
confirmed in a longer term study. Alternatively, some other substance in meat might have 
caused the increases in the markers of bone metabolism during the meat session. Our result 
is contrary to that of Kerstetter et al. (2005), who observed a non-significant trend towards 
a reduction in the rate of bone turnover with a high-protein diet.  
 
The reason for increased NTx excretion during the whole-grain session remains obscure. 
Possibly, the high intake of phytates from unfermented whole-grain inhibited Ca 
absorption, which could have caused an increase in NTx excretion.   
6.2.5 Conclusions about the dietary interventions 
In conclusion, we observed marked differences in metabolic responses to different foods 
and P additives. The effects of high P intake appear to depend on the P sources consumed 
and other nutrients of the P-containing food. P additives commonly used by the food 
industry seem to be absorbed well and increase S-PTH, as shown in previous studies. By 
contrast, P from meat or whole-grains appears not to affect S-PTH. Because of the high Ca 
content, cheese affects bone metabolism favourably. Meat increased bone turnover, 
possibly because of its high protein content. PP-containing products could more likely 
interfere with Ca balance than MP-containing foods due to the Ca-binding property of the 
PP compound. Longer term intervention studies are needed to confirm our results. 
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6.3 Strengths and limitations of the studies 
6.3.1 Phosphorus analyses of foods  
In Studies I and II, the sampling was performed carefully to ensure the representativeness 
of the analyses. By analysing the nationally most popular products in each food category, 
we believe the results are nutritionally relevant. For each analysis, products from different 
batches were bought to exclude the effect of possible variation in nutrient contents 
between batches. Due to the sampling procedure, the representativeness of the results of 
the food studies can be considered better than in several other studies where P contents 
have been measured. Reference materials were used in every batch analysed to 
appropriately report the accuracy and precision of the both TP and DP analyses. These 
data are lacking in most other P analyses published. The recent papers on food P contents 
have concentrated on meats and meat products. We have extended the analyses to foods of 
plant origin, which can be considered another strength of these studies.  
 
The TP contents of the foods were analysed by a routine method, and the results are in 
accord with previously published findings. The analysis of DP is a novel method, the use 
of which provides additional information to the usual TP analyses. The results for DP were 
mostly consistent with previous data on P availability, but they should be confirmed with 
another, in vivo method. In some samples with extremely high DP proportion, the DP 
content slightly exceeded the TP content, which may indicate that the method of DP 
analysis is not equally accurate for all samples. Considering the importance of most P 
sources also as protein sources data analysis of the protein content of the foods would have 
provided more accurate P-to-protein ratios. 
6.3.2 Dietary interventions  
The dietary interventions of this thesis were short-term studies in which the nutrient 
intakes were completely controlled. Based on previous research (Kemi et al. 2006, 
Kärkkäinen & Lamberg-Allardt 1996), the study design is suitable for comparing the 
effects of different P sources. However, as discussed earlier, more frequent sampling 
would have revealed the differences among different sessions in more detail – some of the 
differences may have remained unseen due to the sampling schedules. An increase in the 
number of samples would have required the use of cannulas (instead of repetitive 
punctures), which would have necessitated that the subjects stay at the research unit 
throughout the sessions.   
 
The short follow-up period is a limitation of the studies. Longer term intervention studies 
are needed to confirm our results. However, for comparing absorbability of P from 
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different sources, we believe the 24-h study periods were adequate, as most P is absorbed 
passively.  
 
Problems in designing diets with similar amounts of nutrients using different foods is 
another limitation of the studies. In Study III, the whole food approach can hence be 
considered a limitation. When feeding meat, whole-grains, and cheese in separate sessions, 
the intakes of protein, fibre, and Ca varies among these sessions. We considered the 
possibility of equalizing the intakes of these nutrients by using supplements. However, if 
supplemented, the test diets would not be realistic in representing the nutrient content of 
the P sources. Furthermore, the absorbability of a nutrient could be different between 
foods and dietary supplements. For this reason, a fibre supplement, for instance, should 
have contained identical fibres as the whole-grain foods in the test diet. Such a supplement 
would also have increased P intake as a large part of whole-grain P can be found in the 
fibre part of a grain. In Study IV, the differences in Na intakes between the sessions should 
have been corrected by adding a Na salt to the diet during monophosphate and control 
sessions, even though it is unlikely that the difference in Na intakes affected S-PTH 
(Kärkkäinen & Lamberg-Allardt 1996). 
 
The main outcome variable in both studies was S-PTH. According to power calculation 
based on S-PTH (assuming 80% power with α=0.05), a sample size of 13 was adequate 
(Kemi et al. 2006). However, as intra- and interindividual variation is greater in bone 
formation and resorption markers than in S-PTH, a larger sample size might have better 
revealed differences in these markers, especially considering that the P intakes were 
practically the same during different sessions. 
 
Due to differences in mineral metabolism between men and women (Calvo et al. 1990) 
and between pre- and postmenopausal women (Renier et al. 1992), we focused on one age 
group and gender. This impedes generalization of our results to men and elderly women. 
Thus, in addition to longer term studies on P sources, also comparisons in different subject 
groups, such as in younger and elderly patients and in healthy individuals and CKD 
patients, are needed in the future. 
 
Ideally, measuring more than one bone resorption and formation marker would be optimal, 
as different markers depict different stages of bone metabolism. Furthermore, measuring 
markers of bone metabolism in Study IV would have been interesting. It is unsure whether 
FGF-23 responds to P loads acutely, but measuring its concentrations would at least have 
provided more information on the inter- and intraindividual changes of this marker in 
healthy young women. Due to budget constraints, additional measurements were not 
possible.    
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7 Summary and conclusions 
This thesis provides new information on P content of foods, P absorbability, and the 
effects of different P sources on mineral metabolism. Based on these studies, P is absorbed 
with different efficacy from different foods, and effects of P on health may depend on the 
source from which it is ingested. The latter is explained by differences in absorbability of 
P, but also by other nutrients that each P source contains. Inorganic P used as an additive is 
absorbed more efficiently than P from natural sources and affects mineral metabolism 
negatively. In addition, inorganic P additives often contain Na, which has a negative effect 
on cardiovascular and bone health.       
 
Specific findings of each study were as follows: 
 
Study I: Differences existed in total and in vitro digestible P contents among commonly 
used plant foods and beverages. The highest proportions of DP (87-100%) were found in 
cola drinks, beer, and P additive-containing muffins, the lowest in sesame seeds (6%) and 
legumes (30-42%). In grain products, the DP proportion varied (26-65%) likely depending 
on the grains used, the presence of yeast, and other techonological properties such as 
length of fermentation. Base on this study, legumes and seeds may be relatively poor P 
sources despite high TP content. 
 
Study II: Differences existed in total and in vitro digestible P content of commonly used 
meat and milk products. The highest proportions of DP (70-100%) were found in P 
additive-containing processed cheeses and meat products, the lowest in cottage cheese 
(48%). Chicken, pork, beef, and rainbow trout contained similar amounts of TP (199-232 
mg/100 g), but slightly more variation was found in their DP contents (147-207 mg/100 g). 
Based on these results, variation in both TP and DP contents of similar products can be   
substantial. Generally, foods of animal origin seem to have higher DP amounts and 
proportions than plant foods.     
 
Study III: In the short-term controlled intervention study, different P sources affected 
markers of P, Ca, and bone metabolism differently in healthy young females. Only a P 
supplement containing inorganic P additives increased S-PTH. Meat increased both bone 
formation and bone resorption. Cheese decreased S-PTH and bone resorption, indicating a 
favourable change in bone metabolism. Based on S-Pi and U-Pi, P from unfermented 
whole-grains seems not to be absorbed as efficiently as P from other sources used in this 
study.  
 
Study IV: In the short-term controlled intervention study, mono- and polyphosphates (MP 
and PP, respectively) affected markers of P and Ca metabolism similarly in healthy young 
females. Both MP and PP increased S-PTH, which, in the long run, may have a negative 
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effect on bone. PP decreased U-Ca more than did MP, implying that PP may bind Ca in 
the intestine more than MP.  
 
The results of this thesis suggest that when evaluating effects of P intake on health, the P 
sources should be scrutinized. More research is, however, needed on absorbability of P, for 
example, from differently prepared legumes and grains, but longer term studies on the 
effects of P intake on cardiovascular and bone health are also warranted.  
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Appendix I 
Table 1. Phosphorus contents of selected raw, lean and boneless meats.  
Meat P content mg / 100 g 
Beef 2101 
Chicken 1601 / 2102 
Lamb 1501 
Moose 2201 
Pork 1601 / 2102 
Reindeer 3101 
1Source: National Food Database Fineli®, National Institute for Health and Welfare 
2Source: Sherman & Mehta 2009 
 
Table 2. Phosphorus content of selected plant-based foods. 
Food P content mg / 100 g 
Soy meal 839 
Sunflowerseed 700 
Almond 490 
Lentils green/brown 350 
Dark chocolate 200 
Boiled chick pea  168 
Boiled sweet corn 85 
Tomato  30 
Apple (with skin) 8 
Source: National Food Database Fineli®, National Institute for Health and Welfare 
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Appendix II 
 
Table 1. Phosphate-containing food additives and their E codes and group names. 
E code Additive Group name of additive 
E338 Phosphoric acid 
E339 Monosodium phosphate 
Disodium phosphate 
Trisodium phosphate 
E340 Monopotassium phosphate 
Dipotassium phosphate 
Tripotassium phosphate 
E341 Monocalcium phosphate 
Dicalcium phosphate 
Tricalcium phosphate 
Ortho phosphates 
E343 Monomagnesium phosphate 
Dimagnesium phosphate 
Magnesium phosphates 
E450 Disodium diphosphate 
Trisodium diphosphate 
Tetrasodium diphosphate 
Dipotassium diphosphate 
Tetrapotassium diphosphate 
Dicalcium diphosphate 
Monocalcium diphosphate 
Diphosphates = Pyrophosphates 
E 451 Pentasodium triphosphate 
Pentapotassium triphosphate 
Tripolyphosphates 
E 452 Sodium polyphosphate 
Potassium polyphosphate 
Sodium-calcium polyphosphate 
Calcium polyphosphate 
Polyphosphates 
 
E 541 Sodium aluminium phosphate Aluminium phosphate 
E1410 Monostarch phosphate 
E1412 Distarch phosphate 
E1413 Phosphorylated distarch phosphate 
E1414 Acetylated distarch phosphate 
Starch phosphates 
(Organic P additives) 
Modified from Suurseppä et al. (2001) 
 
 
